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Lung cancer is the leading cause of cancer-related deaths due to conventional therapy 
resistance and metastatic disease, therefore understanding the mechanisms governing 
these biological functions is vital for improving patient survival. Approximately 30% of 
patients with the adenocarcinoma histologic subset of lung cancer possess an 
activating KRAS mutation, characterized by a lack of response to chemotherapies with 
a poor overall 5-year survival rate. Despite the mutational frequency, KRAS remains a 
challenge to pharmacologically inhibit and current drugs undergoing clinical trials that 
target specific downstream effector proteins of KRAS, such as MEK inhibitors, have 
failed to produce significant clinical benefits. Previous studies by our group on the 
metastatic process revealed that malignant lung cancer cells undergo an epithelial-to-
mesenchymal transition (EMT) that is regulated by a double-negative feedback loop 
between the transcription factor Zeb1 and the microRNA-200 family (miR-200). 
Furthermore, these studies demonstrated that mesenchymal lung cancer cell invasion 
and metastasis are dependent on interaction with the extracellular matrix (ECM). In 
addition to metastasis, EMT has been implicated in resistance to radiation and 
chemotherapies as well as resistance to certain targeted drug treatments. Thus, the 
comprehensive objective of this study was to: (1) elucidate the detailed mechanisms of 
metastasis by investigating the collaborative effect of EMT and ECM on KRAS mutant 
lung cancer metastasis, and (2) delineate the mechanism of EMT in promoting MEK 
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inhibitor resistance in KRAS mutant lung cancers. Our findings reveal increased 
collagen deposition in mesenchymal tumor tissues due to amplification of collagen 
gene expression in Zeb1-driven mesenchymal lung cancer cells. Additionally, collagen 
fibers in the metastatic tumor tissues exhibit greater linearity and organization, 
correlating with direct Zeb1-upregulation of the collagen crosslinking enzyme LOXL2. 
Coordinated expression of LOXL2 with collagen increases insoluble collagen 
crosslinking and deposition in the tumor microenvironment, resulting in activated 
Fak/Src signaling to promote metastasis. Using functional in vivo shRNA screens 
coupled with proteomic profiling, we identified Zeb1-driven epithelial-to-mesenchymal 
transition (EMT) as a regulator of MAPK-dependent signaling activity and tumor 
maintenance in lung cancer cells. Mechanistic studies in novel cell line and animal 
models further demonstrated that the Ras-Raf-Mek-Erk MAPK signaling cascade in 
epithelial cells is activated through upregulation of the scaffold protein Il17rd, which is 
directly repressed by Zeb1 during EMT. Translationally, we observe that poorly-
differentiated, mesenchymal lung cancer cells within the heterogeneous lung tumor 
tissue of in vivo models are resistant to MEK inhibitors and identified Zeb1 and Il17rd 
as potential biomarkers from large patient datasets. Reversion of functional EMT by 
genetic expression of miR-200 or treatment with the class I HDAC inhibitor 
mocetinostat sensitized resistant cancer cells to MEK inhibition and significantly 
reduced tumor growth. This study establishes the mechanisms of metastasis and MEK 
inhibitor resistance in KRAS mutant lung cancers, identifies multiple potential 
prognostic markers of metastasis and resistance, and provides pre-clinical evidence for 
a promising combinatorial therapy against lung cancer progression. 
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CHAPTER 1: INTRODUCTION 
 
KRAS Mutant Lung Cancers 
Lung cancer is not only the second leading cause of estimated new cancer 
cases annually (with over 200,000 estimated new cases in the U.S. alone), but it is the 
leading cause of cancer-associated deaths in the United States (>150,000 annual 
deaths in the U.S.) and worldwide, surpassing the successive three cancer types 
combined (1). Patients with lung cancer are often diagnosed with advanced stage 
tumors and metastatic disease, correlating with resistance to chemotherapies and poor 
overall 5-year survival. Furthermore, patients who are treated for early stage disease 
frequently acquire resistance to first-line therapies and ultimately develop metastasis 
(1-5). Therefore understanding the biology orchestrating lung cancer progression, 
therapy resistance and metastasis is vital for improving patient survival. 
Lung cancer can be separated into several different histologic forms. The 
majority of lung cancer patients (~85%) have non-small-cell lung cancer (NSCLC), 
which can be further divided into the lung adenocarcinoma, squamous cell carcinoma, 
and large cell subtypes (6). Approximately 30% of patients with lung adenocarcinoma 
possess a KRAS mutation that activates various downstream signaling pathways to 
promote tumor formation, tumor growth, and metastasis (7, 8). KRAS is a small 
GTPase protein that switches to an “on” or “off” conformational state, which is 
dependent upon its binding to guanosine triphosphate (GTP) or guanosine diphosphate 
(GDP), respectively. This conformational change leads to interactions with other 
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downstream effector proteins, such as Raf or PI3K, that often possess a Ras binding 
domain in their protein structure. KRAS bound proteins are then activated by changes 
in conformation or subcellular localization to other kinases, leading to activation of the 
proteins by phosphorylation of the serine, threonine, or tyrosine amino acid residues. 
Since the downstream target proteins activated by KRAS are typically kinases, this 
catalyzes a signaling cascade to various other kinases which ultimately drives 
expression of genes that regulate tumor formation, growth, survival, and metastases (7, 
9, 10). In the context of cancer, KRAS mutations commonly result in a substitution of an 
amino acid residue, typically at codon 12, which prevents the release of bound GTP, 
retaining KRAS in the activated “on” state. Consequently, constant KRAS activation 
overstimulates various different signaling molecules responsible for tumorigenesis and 
malignancy (7). 
Despite advancements in DNA sequencing technology that allow for the 
identification of KRAS mutations in lung tumors, treating KRAS mutant lung cancer 
patients remains a challenge due to poor response to chemotherapies as well as a lack 
of targetable drugs that can specifically and effectively inhibit the constitutively active 
oncogenic protein. Therefore, current clinical trials target the downstream effector 
proteins of KRAS through the use of MEK inhibitors (11, 12). The Mek 1 and 2 
(Mek1/2) proteins are dual specificity kinases that are part of the mitogen activated 
protein kinase (MAPK) pathway. The canonical MAPK pathway is comprised of the 
RAF-MEK-ERK kinase cascade and is normally activated through growth factor 
receptor tyrosine kinase (RTK) activation of RAS to stimulate the RAS-RAF-MEK-ERK 
pathway. Continual stimulation of this pathway by mutant KRAS leads to high 
phosphorylation of the extracellular signal–regulated kinases 1 and 2 (Erk1/2), resulting 
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in tumor formation and growth (13, 14). Although hyperactivation of MAPK signaling by 
KRAS is typically simplified as a linear model of intracellular communication, in reality, 
the MAPK pathway is a highly complex web of interconnected kinases and regulatory 
proteins. While KRAS alone is sufficient to stimulate MAPK growth, numerous other 
cellular factors are critical at maintaining homeostasis and keeping disregulated growth 
in check. Examples of tumor suppressive regulation include the feedback inhibition by 
the downstream Erk1/2 kinase, expression of MAPK inhibitory proteins and 
phosphatases, and alterations in scaffolding proteins that facilitate signaling activity 
(15-24). The spatial-temporal regulation of MAPK signaling determines the biological 
fate of the cell and each aspect of MAPK regulation can be disrupted during tumor 
progression. 
Although MEK inhibition should theoretically reduce tumor burden in patients by 
suppressing MAPK-associated growth as demonstrated experimentally, recent clinical 
trials with MEK inhibitors have demonstrated no significant improvement in KRAS 
mutant NSCLC patient survival, suggesting resistance mechanisms (25, 26). Co-clinical 
trials utilizing MEK inhibitors with chemotherapy have shown that the acquisition of 
secondary mutations in tumor suppressors, such as TP53 or LKB1, contributes to 
resistance to a combination treatment of docetaxel with the MEK inhibitor selumetinib 
(27). The p53 tumor suppressor protein has countless cellular functions that are critical 
at preventing tumor initiation and progression (28). Although several aspects of the 
intricate biological functions of p53 have been elucidated, the mechanisms of how 
alterations in p53 function and expression promote tumor progression have yet to be 
fully defined (28, 29). Clinically, TP53 is one of the most commonly mutated genes in 
lung cancer, occurring in approximately 50% of all patients (Figure 1) (30, 31).  
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Since rescued expression of a somatically mutated tumor suppressor is not a feasible 
therapeutic option against lung cancer, understanding the precise mechanisms of p53 
mutations on lung tumor progression is vital for identification of novel biomarkers and 
therapeutic targets to overcome drug resistance. 
  
Figure 1. Top: Genetic alterations in KRAS and TP53 in lung adenocarcinoma 
patients from TCGA dataset (Nature 2014). Bottom: Genetic alterations in KRAS 
and TP53 in lung adenocarcinoma patients from TCGA dataset (Broad, Cell 2012). 
Images accessed in May 2017 with permission as described on the cbioportal.org 
website (http://www.cbioportal.org/faq.jsp) and as granted from journals of the 
following references: 
 
Gao, J., B. A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, S. O. Sumer, Y. Sun, A. 
Jacobsen, R. Sinha, E. Larsson, E. Cerami, C. Sander, and N. Schultz. 2013. 
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the 
cBioPortal. Science Signaling 6: pl1-pl1. 
 
Cerami, E., J. Gao, U. Dogrusoz, B. E. Gross, S. O. Sumer, B. A. Aksoy, A. 
Jacobsen, C. J. Byrne, M. L. Heuer, E. Larsson, Y. Antipin, B. Reva, A. P. 
Goldberg, C. Sander, and N. Schultz. 2012. The cBio Cancer Genomics Portal: An 
Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1. 
Cancer Discovery 2: 401-404. 
Figure 1 
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Epithelial-to-Mesenchymal Transition in Lung Cancer Progression 
 Previous work by our group utilizing the spontaneous mutant KrasLA1-G12D/+ 
(Kras) and double-mutant KrasLA1-G12D/+;p53R172HΔg/+ (KP) murine models of lung 
adenocarcinoma demonstrated that co-mutation of p53 with KRAS increased tumor 
formation, displayed more advanced grade lung adenocarcinomas, and produced 
metastasis (32). Further studies on the metastatic process using syngeneic tumor 
models with cell lines derived from the primary and metastatic tumor tissues of the KP 
mice revealed that malignant murine lung cancer cells had undergone an epithelial-to-
mesenchymal transition (EMT) (33). EMT is a biological process essential for human 
development that is involved in tissue expansion and wound repair (34). During EMT, 
polarized, well-differentiated epithelial cells alter various genetic and biochemical 
properties to adopt a more de-differentiated, mesenchymal phenotype. Although the 
terminology suggests a binary transformation, EMT is actually a complex process with 
varying degrees of differentiation states at the molecular level that are regulated by a 
multitude of factors including extrinsic stimuli, transcription factors, and microRNAs (34-
37). From a tumor progression standpoint, EMT is a proposed model of metastasis 
whereby epithelial cancer cells lose their cell-cell adherence junctions and become 
more motile and invasive, resulting in primary tumor dissemination and colonization of 
distant organs (34). In addition to metastasis, EMT has also been implicated as a 
model for resistance to chemotherapies, radiation, and targeted drug therapies (38-43). 
Although a functional role for EMT in the development of therapy resistance is 
frequently observed, the mechanism(s) by which EMT promotes resistance are poorly 
understood in most cases. 
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 Prior studies by our group and others using cell line models and genetically-
engineered murine models demonstrate that EMT is regulated by a double-negative 
feedback loop between the miR-200 family of microRNAs and the Zeb1 transcription 
factor, where high Zeb1 expression promotes the mesenchymal phenotype while high 
miR-200 expression reverses EMT and promotes a mesenchymal-to-epithelial 
transition (MET) state in lung cancer cells (33, 44). MicroRNAs are small, non-coding 
RNAs which, in their mature form, regulate gene expression by typically binding to the 
3’-untranslated region (3’-UTR) of a target mRNA through complementary nucleotide 
base paring. Once bound to the mRNA 3’-UTR, microRNAs hinder translation and/or 
cause mRNA instability and degradation. The miR-200 family consists of five members: 
miR-200a, miR-200b, miR-200c, miR-141, and miR-429. MiR-200a, miR-200b, and 
miR-429 are clustered on the same loci of chromosome 1 in humans while miR-200c 
and miR-141 are clustered on the same loci of chromosome 12. All five miR-200 family 
members bind to the Zeb1 3’-UTR which results in downregulation of Zeb1 expression 
(45-47). Conversely, Zeb1 directly suppresses miR-200 expression by binding onto the 
E-box recognition sites on the promoter region of miR-200 and other epithelial-related 
genes, inhibiting transcription (46-49). Besides transcriptional repression by direct 
promoter hindrance, Zeb1 has been reported to epigenetically silence miR-200 
expression as well (50). Numerous studies by our group and others have demonstrated 
that increased Zeb1 expression in cancer cells leads to greater metastatic propensities, 
enhanced resistance to first-line radiation/chemotherapies, and significantly reduced 
patient survival (38, 45, 48-60). Despite the importance of Zeb1 and miR-200 in 
regulating EMT-induced cancer progression, direct silencing of Zeb1 or direct 
administration of miR-200 presents numerous challenges pharmacologically due to the 
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complicated delivery methods as well as the pleiotropic downstream targets of these 
two genes. EMT also transpires in only a subset of cells within the heterogeneous 
primary tumor tissue (61), which consists of predominantly epithelial cancer cells that 
exhibit distinct responses to treatment. Thus, insights into the downstream targets 
regulated Zeb1/miR-200 to produce functionally relevant phenotypic changes are 
necessary to uncover the contrasting sensitivities to specific targeted therapies 
between epithelial and mesenchymal lung cancer cells as well as define prognostic and 
therapeutic markers against metastasis. 
 
Extracellular Matrix and Metastasis 
 While the cell-intrinsic effects of Zeb1/miR-200 are critical at regulating EMT, 
findings by our group and others have demonstrated that tumor cell-extracellular matrix 
(ECM) interactions play a crucial role in modulating cell behavior, including EMT, 
invasion, and metastasis (33, 58, 62-66). For instance, in vitro three dimensional (3D) 
culture of our metastatic, mesenchymal murine lung cancer cell line in laminin-rich 
Matrigel basement membrane caused the cells to form highly polarized, epithelial 
organoids that only became invasive upon forced induction of EMT by stimulating the 
cell structures with transforming growth factor beta (TGF-β) (33). However, replicating 
the 3D culture conditions of the mesenchymal murine lung cancer cells in an ECM-free 
polyethylene glycol (PEG) hydrogel did not produce invasive structures following TGF-
β treatment, signifying that, both, ECM interaction and modification, is necessary for 
invasion and metastasis (65). Several reports have also suggested that there exists a 
reciprocal dynamic interplay between EMT and the structural/compositional properties 
of ECM that determines the invasiveness of cancer cells (67). Proteomic analyses of 
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our epithelial and mesenchymal lung cancer cell lines uncovered several upregulated 
ECM-associated proteins in mesenchymal cells that could potentially drive metastasis 
(68). A major component of the ECM that has been implicated in promoting EMT and 
driving cancer cell invasion is collagen, which represents the majority of interstitial ECM 
proteins in mammalian tissues (63, 66, 69). There are 29 different collagen isoforms 
encoded by 44 genes that are localized in different components of tissue architecture, 
each contributing to various cellular functions (70). Mature fibrillar collagen molecules 
are comprised of three individual collagen fibrils that form a triple-helical structure, with 
collagen type I being the most abundant fibrillar collagen isoform in mammals (63, 71). 
 Collagen type I has been implicated in tumor progression as well as promoting 
metastasis (62, 72-74). Collagen binding to cancer cells through various receptors 
regulates different cancer cell behaviors including cell adhesion, tumor growth, invasion 
and metastasis, and drug resistance. The maturation process for collagen type I fibers 
is extensive and requires multiple tiers of post-translational modifications (71). Collagen 
type I consists of two isoforms expressed by the genes COL1A1 and COL1A2 that 
synthesize the α1 and α2 chains in the endoplasmic reticulum, respectively. Two α1 
and one α2 chains form intramolecular covalent bonds that result in the triple-helical 
structure of an immature procollagen molecule. To form the intramolecular covalent 
bonds, the lysine and proline amino acid residues in each chain are hydroxylated by 
various enzymes of the lysyl hydroxylase family to stabilize the helical structure. The 
procollagen molecules are then secreted into the extracellular space where the N- and 
C-terminus propeptides are cleaved off by metalloproteinase to form an individual 
mature collagen fiber. However, individual mature collagen fibers are still soluble and 
are prone to degradation by various enzymes. In order to obstain insoluble collagen 
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deposition in the microenvironment, the mature triple-helix collagen fibers must endure 
further crosslinking through extracellular, intermolecular covalent bonds. This process 
is facilitated by the lysyl oxidase (LOX) family of enzymes. The LOX family possesses a 
conserved catalytic region that deaminates the lysine amino acid residues on proteins 
including collagen. Once deaminated, the lysine residues form covalent bonds with the 
aminated ε-amine group of other lysine residues on collagen to spontaneously form 
inter-collagen crosslinks (71). The crosslinked collagen becomes insoluble and 
stabilizes in the tumor microenvironment, activating various collagen binding receptors 
that promote invasion and metastasis (58, 63). 
 Though the presence of collagen is correlated with tumor progression, numerous 
studies have shown that collagen requires LOX crosslinking to increase matrix stiffness 
and promote cancer cell invasiveness and malignancy (33, 65, 75-78). LOX enzymes 
are developmentally necessary for insoluble collagen maturation and deposition in 
tissues (66, 79). There are five LOX isoforms with a conserved catalytic domain at the 
C-terminus end of the protein while the N-terminus regions are variable, giving rise to 
differential localization, protein targets, and functional regulation (80). Upregulation of 
the LOX and LOXL2 isoforms has been shown to promote invasion and metastasis in 
certain cancer types (80) but due to the N-terminus posttranslational modifications as 
well as the non-specific nature of the lysine deamination process, LOX and LOXL2 also 
have non-ECM, intracellular roles in promoting metastasis (81-86). Although LOX has 
been reported to promote fibrosis-mediated breast cancer metastasis, there has been 
little work establishing their role in lung cancer systems. Furthermore, the relationship 
between EMT, the LOX family, and the ECM in regulating lung cancer metastasis is still 
poorly understood. 
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Dissertation Objectives 
 This dissertation is sectioned into two projects that describe the role of EMT on 
KRAS mutant lung cancer progression. The first project aims to determine the 
cooperative mechanisms of EMT and ECM on lung cancer invasion and metastasis. 
The second study aims to identify differences in therapeutic vulnerabilities between 
epithelial and mesenchymal KRAS mutant lung cancer cells as well as delineate the 
mechanisms behind MEK inhibitor resistance. 
 First, we demonstrate that mesenchymal lung cancer cells drive invasion and 
metastasis by increasing collagen deposition, crosslinking, and stabilization in their 
surrounding microenvironment due to an increase in Zeb1-driven LOXL2 expression. 
The increase in collagen deposition results in the activation of focal adhesion signaling, 
which we have previously demonstrated to be involved in lung cancer invasion and 
metastasis (58). Functional in vitro and in vivo assays establish LOXL2 as a potential 
therapeutic target for the prevention of lung cancer metastasis. Pathological analyses 
of our KP murine model as well as human lung cancer patient tissues define collagen 
type I and type III as promising prognostic markers. 
 Next, we sought to understand the differences in therapeutic vulnerabilities 
between epithelial and mesenchymal lung tumors through the use of in vivo short 
hairpin RNA (shRNA) library screens and identified greater dependency on MAPK 
signaling molecules for tumor initiation and maintenance in epithelial cells. Proteomic 
profiling and in-depth mechanistic analyses in murine and human cell line and multiple 
animal models revealed higher MAPK signaling proteins in epithelial cells and 
demonstrated that MAPK pathway activation is dependent on the scaffold protein Il17rd 
(Sef1/Il17rlm/Hh18), which is directly repressed by Zeb1 during EMT. Therapeutically, 
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both in vitro and in multiple genetic animal models, epithelial lung cancer cells (low 
Zeb1, high Il17rd) are very responsive to MEK inhibition while mesenchymal cells (high 
Zeb1, low Il17rd) are resistant. Moreover we demonstrate that suppression of Zeb1 
function through genetic induction of miR-200 or inhibition of class I histone 
deacetylases (HDAC) with mocetinostat sensitized mesenchymal lung cancer cells to 
MEK inhibitors. Histologic and bioinformatics analyses of large human patient sample 
sets revealed an inverse correlation of Zeb1 and activated MAPK (p-Erk) or ZEB1 and 
IL17RD expression, respectively. Our study identifies distinct well- and de-differentiated 
subpopulations of lung cancer cells with differential sensitivities to MEK inhibition, 
defines Zeb1 and Il17rd as the causative mechanism and potential biomarkers that 
predict sensitivity to treatment, and presents a prospective combinatorial therapeutic 
strategy to overcome resistance. 
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CHAPTER 2: MATERIALS AND METHODS 
 
Project 1: ZEB1 Induces LOXL2-Mediated Collagen Stabilization and Deposition 
in the Extracellular Matrix to Drive Lung Cancer Invasion and Metastasis 
 
Contents of this chapter are derived from the publication Peng DH, Ungewiss C, Tong 
P, Byers LA, Wang J, Canales JR, Villalobos PA, Uraoka N, Mino B, Behrens C, 
Wistuba II, Han RI, Wanna CA, Fahrenholtz M, Grande-Allen KJ, Creighton CJ, 
Gibbons DL. “ZEB1 induces LOXL2-mediated collagen stabilization and deposition in 
the extracellular matrix to drive lung cancer invasion and metastasis.” Oncogene. 2016 
Oct 03. PubMed PMID: 27694892 with approval from Nature Publishing Group. 
 
Plasmids and Reagents 
Mouse LOX shRNA constructs were purchased from Thermo Fisher Scientific (Cat#: 
RMM4534-EG16948, Grand Island, NY). Mouse LOXL2 shRNA constructs were cloned 
the pLKO.1 lentiviral vector. Murine LOX and LOXL2 isoforms were cloned and 
expressed using the Doxycycline inducible pTRIPz-GFP lentiviral vector. Viral vectors 
were the psPAX2 packaging and pMD2.G envelope vectors. Luciferase 3’-UTR 
reporter constructs were made by reverse-transcription PCR (RT-PCR) and PCR 
amplification of ~2.9 kb and ~2.6 kb of mouse LOX and LOXL2 3’-UTR mRNA, 
respectively. The promoter region for LOXL2 was PCR amplified from mouse genomic 
DNA ~1.3 kb upstream of the transcriptional start site. Site directed mutagenesis of 
binding sites were performed using the QuikChange II XL Site-Directed Mutagenesis 
Kit (Agilent, Santa Clara, CA, USA). 
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Analysis of Human Cancer Datasets 
Level 3 gene expression data from the TCGA pan-cancer data sets were used (87, 88). 
EMT score was calculated based on the EMT signature previously published (40, 53). 
Pearson correlation was used to quantify the association between EMT and collagen 
expression. To investigate if collagen family genes were enriched with strong 
correlations with EMT, we compared the correlations between EMT score and collagen 
family genes and correlations between EMT score and non-collagen family genes using 
the Kolmogorov–Smirnov test. For analysis of collagen-associated mRNA expression 
and lung cancer patient survival, we examined a previously-assembled compendium 
dataset (89) of 11 published expression profiling datasets for human lung 
adenocarcinomas (n = 1,492 tumors), with the addition of another dataset from Sato et 
al (90), patients represented in both Shedden and Chitale datasets (n=88 patients) 
were first removed from the Shedden dataset, and one patient from the Bild dataset 
thought to potentially represent SQCC was also removed (leaving n = 1,586 tumors in 
total). 
 
Cell Culture and Transfections 
All lung cancer cell lines were cultured in RPMI 1640 supplemented with 10% fetal 
bovine serum (FBS). HEK-293 cells were cultured in DMEM supplemented with 10% 
FBS. Lentiviral vectors were co-transfected in HEK-293 cell with Lipofectamine LTX 
(Thermo). Luciferase reporter assays used Lipofectamine 2000 (Thermo) as the 
transfection reagent. Murine cell lines were previously generated by our lab (33) and 
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human cell lines were obtained through ATCC. All cell lines were verified to by 
mycoplasma negative monthly. 
 
QPCR and Western Blotting 
Total RNA was isolated from cells by TRIzol (Thermo) according to manufacturer 
protocol and cDNA was generated using iSCRIPT reagents (Bio-Rad, Hercules, CA). 
QPCR assays were performed using SYBR Green PCR Master Mix (Thermo) and 
normalized to the L32 gene. Cell lysates were prepared according to the RIPA buffer 
protocol (CS9806), separated by SDS-PAGE, transferred to nitrocellulose membranes, 
and probed with listed antibodies. 
 
Luciferase Reporter Assays 
Luciferase reporter assays were carried out by transfection of 500 ng of the reporter 
constructs in specified cell lines with 50 nM miR-200a/b/c precursors where appropriate 
(Thermo). Assays were carried out using Dual-Luciferase Reporter Assay kit (Promega, 
Madison, WI). 
 
Chromatin Immunoprecipitation Assays 
Chromatin immunoprecipitation assays were performed as previously described (48, 
91). Immunoprecipitation was carried out using an anti-ZEB1 antibody or mock IgG 
control (Santa Cruz, Dallas, TX). Promoter segment enrichment was analyzed by 
qPCR using primers flanking the potential ZEB1 binding sites along the LOXL2 
promoter. 
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Migration and Invasion Assays 
Migration/invasion assays were performed using 8 µm Transwell inserts pre-coated 
with Matrigel or 100 µl of 0.2 mg/ml collagen type I (BD Biosciences, San Jose, CA). 
Assays progressed at 37oC for 8 hrs for human cell lines and 20 hrs for murine cell 
lines following a published protocol (33). BAPN and D-Penicillamine were purchased 
from Sigma (St. Louis, MO). Inserts were stained with crystal violet and cells were 
imaged by bright field microscopy and counted using ImageJ software. 
 
3D Matrigel and Matrigel/Collagen Culture 
Glass 8-well chamber slides (Thermo) were coated with 100 µl Matrigel or 
Matrigel/collagen type I mix at 1.5 mg/ml final collagen concentration. Cells were 
seeded in the matrices and cultured for 7 days with indicated daily treatments. Collagen 
gels for SEM analysis were 2 mg/ml of pure collagen with cells encapsulated and 
treated with TGF-β for 7 days. 
 
Syngeneic In Vivo Tumorigenesis and Metastasis Assays 
Cells were subcutaneously injected in the right flanks of male, syngeneic 129/sv mice 
at 3 months of age and allowed to form tumors for 5 to 6 weeks. After euthanasia, 
tumors were measured and lung metastatic nodules were quantified. For in vivo 
inhibitor treatments, mice received 100 mg/kg BAPN or 150 mg/kg D-Pen in H2O or 
PBS, respectively, by daily intraperitoneal injection. Lung tissues and primary tumor 
tissues were formalin fixed, paraffin embedded, and sectioned for further analysis. All 
animal experiments were reviewed and approved by the Institutional Animal Care and 
Use Committee at The University of Texas MD Anderson Cancer Center. 
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Immunohistochemistry (IHC) and Second Harmonics Generation (SHG) 
Paraffin embedded tissue sections were rehydrated, blocked with goat serum, and 
probed with listed antibodies. Tissues were subsequently washed and probed with 
HRP-conjugated secondary antibodies and signal was attained by developing with a 
DAB reagent. For SHG microscopy, tissues stained by H&E were visualized using a 
Zeiss LSM 7 MP Multiphoton Microscope at an excitation wavelength of 800 nm and 
collagen fiber signals were detected at 380-430 nm using bandpass filters. Collagen 
linearity was calculated as a ratio of the total length versus the end-to-end length of the 
individual collagen fiber as previously described (62). 
 
Immunofluorescence (IF) Staining 
IF stains were performed as previously described (58), stained with listed antibodies 
and visualized by fluorescence microscopy. 
 
Proliferation Assay 
Cells were seeded in 96-well plates at 500 cells/well and treated with BAPN or D-Pen 
at specified concentrations. Proliferation was measured following the WST-1 (Roche, 
Basel, Switzerland) protocol and absorbance was measured at 450 nm after 2 hours. 
 
Amplex Red Assay 
LOX family enzyme activity from cell culture media with indicated treatments was 
measured using the Amplex Red protocol (Thermo) and 2mM benzylamine (Sigma). 
 
17 
 
Mechanical Testing 
A bioindenter (BHT, Anton Paar, Ashland, VA) was used to test the local mechanical 
properties of tumor tissues approximately 1 cm wide under hydrated conditions and 
carried out using a 500 μm diameter flat punch indentation tip with a constant loading 
rate up to a maximum load of 60 μN. Instrumentation software analysis of the resulting 
unloading curve by the Oliver & Pharr method was used to calculate the indentation 
modulus (92). 
 
Cell macerated scanning electron microscopy 
A modification of the NaOH cell-maceration technique reported by Rossi was used 
(93). This technique dissolves the cellular elements, fixed, and dehydrated, leaving 
behind the collagen matrix, network, allowing three-dimensional imaging using SEM. 
Dehydrated specimens were critical point dried (Critical Point Dyer 850, Electron 
Microscopy Science, Hatfield, PA), mounted on aluminum mount (Electron Microscopy 
Science, Hatfield, PA), sputter coated with 15 nm gold palladium in a Denton Desk V 
sputter (Moorestown, NJ), and viewed in a FEI Quanta 400 ESEM FEG (Hillsboro, 
Oregon). 
 
Collagen Fiber Alignment Analysis 
A custom-written MATLAB program was used to analyze the alignment of the collagen 
fibers within the SEM images. The program imported the SEM .tiff files, enhanced the 
grayscale contrast, applied a filter and a mask to reduce white noise and detect the 
fiber edges, respectively (94). The program then developed a high-resolution histogram 
(with 0.5 degree bins) of the fiber directions and set the mean fiber direction at 0 
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degrees. After preparing this histogram for each SEM image, the distributions from 
multiple pictures taken from each gel were compiled to obtain an accurate 
representation of the alignment of each gel. The compiled histogram data from each 
gel was averaged across all gels within a treatment group and then fit to a normal 
distribution. Because the compiled data sets were extremely large, before performing a 
statistical analysis the data was subsampled to retain only one out of every hundred 
points within each 0.5 degree bin. 
 
Statistics 
Statistical analysis was performed with unpaired student’s t-test or otherwise stated. 
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Project 2: Epithelial-mesenchymal transition promotes MEK inhibitor resistance 
in KRAS mutant lung cancers through suppression of IL17rd 
 
Mice 
All animal experiments were reviewed and approved by the Institutional Animal Care 
and Use Committee (IACUC) at The University of Texas MD Anderson Cancer Center. 
The miR-141/200cfl/+ mice contained a cassette (95, 96) bearing a LacZ reporter gene 
and loxP sites flanking the Mirc13tm1Mtm allele on chromosome 6 that targeted the 
Mir141 and Mir200c genes. Mice were purchased from the Mutant Mouse Resource & 
Research Centers (MMRRC) and were initially of the C57BL/6 background upon 
receipt. Subsequently, miR-141/200cfl/+ mice were bred with the 129/sv mice and 
backcrossed for at least 3 generations to obtain a background >50% genetically related 
to the 129/sv background. The miR-141/200cfl/+ mice were then crossed with the 
KrasLSL-G12D mice to generate the KrasLSL-G12D;miR-141/200cfl/+ mouse model. Male and 
female KrasLSL-G12D, KrasLSL-G12D;p53fl/+, and KrasLSL-G12D;miR-141/200cfl/+ adeno-Cre 
inducible mouse models (129/sv background) of lung adenocarcinoma were infected 
with virus by intratracheal intubation at 3 months of age. Experiments with the inducible 
mice were performed 3 months post-infection when tumors properly formed and could 
be visualized by micro-CT imaging. For experiments with the syngeneic tumor 
xenograft assays, male wild-type 129/sv mice ages 3 months and up were used. For 
experiments with the spontaneous KrasLA1-G12D and KrasLA1-G12D/+;p53R172H∆g/+ mouse 
models of lung adenocarcinoma (129/sv background), male mice between the ages of 
6 to 8 months were used. For drug treatment experiments, mice were randomly 
assigned to either treatment or solvent vehicle control groups. For the inducible mouse 
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models, an even number of male and female mice were randomly assigned to receive 
either treatment or vehicle control. Inducible mice that required administration of 
adenovirus were housed specifically in suites designated for biohazardous handling as 
approved by the IACUC protocol. Two weeks post-infection, mice were returned to the 
regular housing suite. All mice were immunocompetent and assessed for health daily 
by the Department of Veterinary Medicine and Surgery (DVMS). All mice were 
genotyped to determine the mutational status by tail snips 2 weeks after birth. 
 
Cell Lines 
BEAS2B cell lines as well as human and murine lung cancer cell lines were cultured in 
RPMI 1640 (Gibco, Thermo Fisher Scientific, Grand Island, NY, USA) supplemented 
with 10% fetal bovine serum (FBS, Gibco). 293T cells were cultured in DMEM (Gibco) 
supplemented with 10% FBS. All human cell lines were obtained through ATCC 
(Manassas, VA, USA). Murine cell lines and manipulated cell lines were derived as 
previously described (33, 41, 53, 55, 56, 58, 89). BEAS2B cell lines were generously 
provided by Dr. Yanan Yang and generated as previously published (59). All cells were 
cultured at 37oC in a humidified incubator at 5% CO2 and verified on a monthly basis to 
by mycoplasma negative using LookOut Mycoplasma PCR Detection Kit (Sigma-
Aldrich, St Louis, MO, USA). Cell lines with inducible Zeb1 or miR-200 expression were 
treated with a final concentration of 2 µg/mL Doxycycline (Dox) from Sigma-Aldrich. 
 
Plasmids, Transfections, and Lentiviral Generation and Transduction 
All shRNAs used in the experiment were expressed in the pLKO.1-puro vector with a 
scramble sequence as the non-targeting control. All cDNAs expressing the open 
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reading frame (ORF) of indicated proteins were cloned into the pLenti-puro vector using 
primers listed in Supplementary Table S6. For transient shRNA or cDNA expression, 
vectors were transfected using the Lipofectamine LTX transfection reagent (Thermo 
Fisher Scientific). Transfection of siRNAs was performed using the Dharmafect reagent 
(GE Dharmacon, Lafayette, CO). For lentiviral transductions, viruses were first 
generated by co-transfecting packaging vector psPAX2, envelope vector pMD2.G, and 
the pLenti-puro expression vector into 293T cells using Lipofectamine LTX. 
Transfection media was removed and 293T cells were cultured in RPMI 1640 
supplemented with FBS for 48hrs. Viruses were then syringe filtered through a 0.45 µm 
nylon filter and Polybrene (Santa Cruz, Dallas, TX) was added to a final concentration 
of 8 µg/mL. Media containing lentiviruses were then added to cells, infected for 48hrs, 
and replaced with fresh media for further experiments. 
 
In vivo/In vitro shRNA screens and analytics 
Murine lung cancer cell lines (393P and 344P) were infected at a multiplicity-of-
infection (MOI) of 0.3 with a pooled shRNA lentiviral library targeting 191 genes 
associated with FDA-approved target therapies (10 shRNA/gene, for target list see 
TableS1b). In parallel in vivo and in vitro screens were executed in at 1000X coverage 
and the shRNA-coupled barcodes were detected deploying high-throughput 
sequencing technology (for detailed procedures and primer sequences see the 
following reference) (97). In-vivo and in vitro screens were carried out in triplicate, and 
duplicate respectively. Raw counts for the screen endpoints and a reference 
population, isolated after transduction, were normalized using the variance stabilizing 
transformation in R with the DESeq2 in R. The normalized counts we divided by the 
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reference to estimate a fold change in barcode abundance. Four independent shRNA 
targeting essential genes (Rpl30, Psma1) or Luciferase (LUC) were cloned with 5 
unique barcodes each and incorporated in the library as positive and negative controls 
(20 reagents/control, see TableS1A). One LUC hairpin showed apparent off-target 
effect, and this trend has been observed over a wide-spectrum of in-vitro and in-vivo 
screens (data not shown). One hairpin for PSMA1 did not show robust drop out, 
however as the trend was consistent across the 5 barcodes, this result was not 
reflective of poor screen performance. The separation of positive and negative controls 
was evaluated by the robust strictly standardized mean (SSMD*, Table S1A), excluding 
the hairpins mentioned above. Fold change distribution was converted to percentiles, 
and biological replicates were collapsed for RSA analysis. The RSA logP-values and 
ranks are provided in Table S1B. 
 
Reverse Phase Protein Array (RPPA) Preparation and Analysis 
Cultured cells described above were washed with PBS and proteins were extracted by 
the addition of lysis buffer (1% Triton X-100, 50 mM HEPES [pH 7.4], 150 mM NaCl, 
1.5 mM MgCl2, 1 mM EGTA, 100 mM NaF, 10 mM NaPPi, 10% glycerol, 1 mM 
phenylmethylsulfonyl fluoride, 1 mM Na3VO4, and protease and phosphoprotease 
inhibitors from Roche, Basel, Switzerland), incubated on ice for 20 minutes, spun down 
at 14,000 rpm for 10 minutes, and collected for supernatant. Protein concentration was 
measured using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) and 
protein samples were prepared to a final concentration of 1 µg/µl mixed with 4x SDS 
sample buffer (40% glycerol, 8% SDS, 0.25M Tris-HCl pH 6.8, 10% 2-
mercaptoethanol) to produce a 1x SDS sample buffer solution. Protein samples were 
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then boiled at 100oC for 5 minutes and stored at -80oC for RPPA processing described 
here: (https://www.mdanderson.org/research/research-resources/core-
facilities/functional-proteomics-rppa-core/rppa-process.html). For analysis of RPPA 
data, a linear mixed model was applied to compare protein levels on a protein-by-
protein base between epithelial and mesenchymal groups; the model includes cell line 
effects as a random effect factor. The resulting p-values were modeled by a Beta-
Uniform Model (BUM). To select protein markers differentially regulated in epithelial 
and mesenchymal phenotypes, we used False Discovery Rate (FDR) of 0.05 as cutoff. 
The heatmap was generated based on mean adjusted expression level by each cell 
line. The Pearson correlation was used for distance matrix calculation and Ward 
method was applied as linkage rule for the hierarchical clustering. 
 
Protein Isolation from Cell Lines and Western Blotting Analysis 
Cultured cells were washed with PBS and proteins were extracted from cell lysates 
using 1x RIPA buffer (Cell Signaling, Danvers, MA) with protease and 
phosphoprotease inhibitors, scraped off the plate with cell scrapers, and transferred 
into 1.5 mL centrifuge tubes. Cell lysates were then sonicated on ice using Vibra-Cell 
VCX130 Sonicator (Sonics & Materials, Inc., Newtown, CT) at 30% amplitude with 2-
second sonication and pulse intervals and 1-second rest intervals for 10 cycles. 
Lysates were then centrifuged at 14,000 rpm for 10 minutes and supernatant was 
collected for protein concentration estimation using the Pierce BCA Protein Assay Kit. 
For Western blotting analysis, protein samples were mixed with 5x SDS Sample Buffer 
(0.3M Tris-Base, 10% SDS, 50% Glycerol, 5% 2-mercaptoethanol, and 0.025% w/v 
Bromophenol Blue) to obtain a final 1x concentration of SDS Sample Buffer. Samples 
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were boiled at 100oC for 10 minutes, incubated on ice for 10 minutes, loaded onto a 
10% SDS polyacrylamide gel, separated by SDS-PAGE, and transferred to a 
nitrocellulose membrane at 100 volts for 2 hours. Membranes containing the 
transferred proteins were then washed with TBS (20mM Tris-Base, 150mM NaCl, pH 
7.6) added with 0.1% Tween-20 (TBST) and blocked with 5% w/v fat free dry milk (Bio-
Rad, Hercules, CA) dissolved in TBST. Membranes were then probed with listed 
primary antibodies diluted in 1% w/v bovine serum albumin (BSA) dissolved in TBST 
overnight at 4oC. Next, antibodies were removed, membranes were washed three 
times with TBST, and horse radish peroxidase (HRP) conjugated secondary antibodies 
diluted in blocking solution were added to the membranes and incubated at room 
temperature for 1 hour. Following the addition of secondary antibodies, membranes 
were washed three times with TBST and HRP-induced chemiluminescence signal was 
produced using Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific). ECL 
signal from antibody probed protein was detected using autoradiography film 
(BioExpress, Kaysville, UT) and developer. 
 
RNA Isolation and qPCR Analysis 
Cultured cells were washed with PBS and total RNA was isolated using TRIzol 
Reagent (Thermo Fisher Scientific). Chloroform was added to the TRIzol solution at a 
1:5 v/v ratio, mixed, and centrifuged at 12,000 rpm for 15 minutes at 4oC. The clear, 
upper liquid phase of the separated solution was collected and equal volumes of 100% 
isopropanol was added, mixed, and centrifuged at max speed for 10 minutes. 
Precipitated RNA was washed twice by adding 75% ethanol and centrifuged at max 
speed for 5 minutes. RNA was air dried on ice for 20 minutes, resuspended in nuclease 
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free water, and RNA concentration was measured using 260/280 nm 
spectrophotometry. For qPCR analysis of mRNA expression levels, cDNA was first 
generated from 2 µg of purified mRNA using qSCRIPT reverse transcriptase mix 
(Quanta Biosciences, Beverly, MA). QPCR assays were performed using SYBR Green 
PCR Master Mix (Thermo Fisher Scientific) along with primers listed in Supplementary 
Table S6 and normalized to the L32 gene. For qPCR analysis of microRNA expression 
levels, reverse transcription was first performed on purified RNA using the TaqMan 
MicroRNA RT Kit (Applied Biosystems, Foster City, CA) and primers specific for the 
microRNA. QPCR assays were performed using the TaqMan Universal qPCR Master 
Mix (Applied Biosystems) along with labeled primer probes specific to the microRNA 
listed in Supplementary Table S6 and normalized to miR-16. All qPCR reactions were 
performed using the 7500 Fast Real-Time PCR System (Applied Biosystems). 
 
Chromatin Immunoprecipitation (ChIP) and qPCR Analysis 
Zeb1 ChIP was performed following previously reported protocol (48). Briefly, an equal 
number of epithelial and mesenchymal human lung cancer cell lines were washed with 
PBS, trypsinized, resuspended in 15 mL conical tubes, crosslinked with 1% 
formaldehyde at room temperature for 10 minutes, washed with PBS, and incubated in 
lysis buffer (50 mM Tris-HCl, pH 8.1, 1% SDS, 10 mM EDTA, and 
protease/phosphatase inhibitor cocktail) on ice for 10 minutes. Cells were then 
sonicated on ice using 50% amplitude with 10-second pulse intervals and 10-second 
rest intervals for 20 cycles. Samples were then centrifuged at 14,000 rpm for 5 minutes, 
supernatant was collected, and immunoprecipitated with 2 µg of Zeb1 antibody or 
rabbit IgG (Santa Cruz) and rotated at 4oC overnight. Pre-cleared protein A/G agarose 
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beads (Santa Cruz) were added to each sample and rotated at 4oC for 2 hours. Beads 
were then centrifuged down at 3,000 g for 2 minutes at 4oC, sequentially washed with 
Wash Buffer 1 (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 150 
mM NaCl), Wash Buffer 2 (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl 
pH 8.1, 500 mM NaCl), Wash Buffer 3 (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 
mM EDTA, 10 mM Tris-HCl pH 8.1), and Tris-EDTA (1 mM EDTA, 10 mM Tris-HCl pH 
8.1). Immunoprecipitated DNA was eluted using Elution Buffer (1% SDS, 0.1 M 
NaHCO3) and incubated at 65oC overnight. DNA was purified using QIAquick PCR 
Purification Kit (Qiagen, Valencia, CA) and 50 ng of eluted DNA was used for each 
qPCR reaction using primers, listed in Supplementary Table S6, flanking potential Zeb1 
promoter binding sites to quantify relative ChIP signal. 
 
Luciferase Reporter Assay 
IL17RD promoter region was cloned from the extracted genomic DNA of H441 cells 
and inserted into the pGL3-promoter vector (Promega, Madison, WI, USA). Mutations 
of Zeb1 binding sites were carried out using the QuikChange II XL Site-Directed 
Mutagenesis Kit (Agilent, Santa Clara, CA, USA). Luciferase reporter assays were 
carried out by co-transfection of 500 ng of the reporter pGL3 constructs with 50 ng of 
the pRL-TK renilla luciferase vector (Promega) in H441 cells with inducible GFP or 
Zeb1 using Lipofectamine 2000 (Thermo Fisher Scientific). Assays were carried out 
using Dual-Luciferase Reporter Assay System (Promega) where renilla signal was 
used as an internal control. Relative luciferin signal was normalized to signal from the 
empty pGL3 promoter vector control. Primers used to clone the IL17RD promoter 
region and generate the Zeb1 mutants are listed in the STAR Methods.  
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In vitro Drug Response and Cell Growth Assays 
Cells were seeded in 96-well plates at 1,000 cells per well and each row was treated 
with the indicated concentrations of drug inhibitors where the first row is the solvent 
control that does not contain any drug. After 72hrs of drug inhibitor treatments, media 
was removed and WST-1 (Roche) colorimetric cell proliferation reagent was added to 
each well, incubated at 37oC for 2 hrs and color intensity measured at 450 nm with 690 
nm reading subtracted for background. Percent surviving fraction of cells were 
normalized against cells treated with solvent control only. 
 
In vivo Drug Response and Tumor Growth Assays 
For in vivo tumor growth assays with transplantation of mouse lung cancer cell lines 
into syngeneic wild-type mice, cells were injected subcutaneously into the right flanks 
of male 129/sv mice at 3 months of age and allowed to form tumors for 3 to 4 weeks 
when tumor volumes were approximately 150 to 200 mm3 measured using digital 
calipers. For induced mouse models of lung adenocarcinoma, adenovirus-expressing 
Cre recombinase was administered into mice lungs at 3 months of age by intratracheal 
intubation at a viral titer of 2.5x107 viruses per mouse. After 3 months post-induction, 
mice lungs were visualized by micro-CT scans to validate tumor formation and 
measure tumor areas. For spontaneous mouse models of lung adenocarcinoma, mice 
approximately 7 months of age were scanned by micro-CT to validate lung tumor 
formation and measure tumor areas. Selumetinib and mocetinostat were administered 
daily by oral gavage at a dosage of 25 mg/kg mouse weight and 80 mg/kg mouse 
weight, respectively. Tumor sizes were measured weekly after treatment began. 
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Selumetinib was dissolved at 5 mg/mL in solvent (4% DMSO, 30% PEG 300, 5% 
Tween 80) and mocetinostat was dissolved at 25 mg/mL in solvent (30% PEG 400, 
0.5% Tween 80, 5% propylene glycol). Control mice received solvent at a volume equal 
to the drug dosage using calculations at the indicated drug concentrations. Mice 
weights were measured weekly to adjust total dosage and assess drug combinations 
on mice health. After euthanasia, syngeneic primary tumors and/or mice lungs were 
formalin fixed, paraffin embedded, and sectioned for histological analysis. 
 
Immunohistochemistry (IHC) 
Paraffin-embedded tissue sections were rehydrated and antigen retrieval was 
performed using citrate buffer, pH 6.0 (Dako Agilent Technologies, Santa Clara, CA) 
and boiled for 25 minutes. Endogenous peroxidases were blocked with 3% H2O2 in 
TBS and slides were further blocked with 5% goat serum in TBST. Tissues were 
probed with indicated primary antibodies diluted in goat serum overnight at 4oC. 
Antibody dilutions are as follows: Zeb1 (1:200), E-cadherin (1:300), Vimentin (1:150), p-
Erk (1:250), p-Mek (1:100). Slides were then washed three times with TBST and 
incubated with streptavidin conjugated secondary antibodies targeting rabbit IgG 
diluted in goat serum for 1hr at room temperature. Slides were washed again and 
incubated with biotinylated HRP in goat serum for 30 minutes at room temperature. 
After washing, signal was attained by developing with DAB reagent (Dako) for 5 
minutes at room temperature. Slides were washed with ddH2O to stop the reaction and 
then stained with Harris Hematoxylin (Thermo Fisher Scientific) for 1 minute and rinsed 
with warm tap water for 5 minutes. Slides were dunked eight times in 0.25% HCl in 
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70% ethanol and rinsed with tap water again for 5 minutes. Slides were dehydrated and 
mounted for further analysis by bright field microscopy. 
 
Analysis of Human Cancer Dataset and Lung Cancer Cell Line Panel 
EMT score was calculated based on the EMT signature previously published (40, 53). 
Gene expression data from the PROSPECT lung adenocarcinoma dataset as well as a 
panel of 77 human lung cancer cell lines were used. Spearman correlation was used to 
quantify the association between EMT score/Zeb1 with IL17RD expression. 
 
Statistics 
Unless specified in the above methods, figures, or in-text, all assays were performed 
using technical triplicates with three experimental replicates for each assay so that a 
significance p-value less than 0.05 indicates statistical significance using student’s t-
test. 
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CHAPTER 3: RESULTS 
 
Project 1: ZEB1 Induces LOXL2-Mediated Collagen Stabilization and Deposition 
in the Extracellular Matrix to Drive Lung Cancer Invasion and Metastasis 
 
Contents of this chapter are derived from the publication Peng DH, Ungewiss C, Tong 
P, Byers LA, Wang J, Canales JR, Villalobos PA, Uraoka N, Mino B, Behrens C, 
Wistuba II, Han RI, Wanna CA, Fahrenholtz M, Grande-Allen KJ, Creighton CJ, 
Gibbons DL. “ZEB1 induces LOXL2-mediated collagen stabilization and deposition in 
the extracellular matrix to drive lung cancer invasion and metastasis.” Oncogene. 2016 
Oct 03. PubMed PMID: 27694892 with approval from Nature Publishing Group. 
 
Expression of collagen and ECM-associated genes correlates with EMT 
To determine if EMT alters the expression of ECM-associated genes, we correlated 
gene expression patterns of patient tumor samples across multiple tumor types from 
the TCGA dataset to our previously reported 76-gene EMT signature score (40). The 
analysis revealed numerous ECM genes that have significant positive correlation with 
EMT (r>0.5) in at least six different epithelial tumor types (Figure 2-5 and Table 1). 
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Figure 2. Representative plot correlating gene expression of collagen 1A1 to EMT 
scores of human tumors from TCGA datasets (BASAL: Basal-like breast cancer; 
BCLA: Bladder Urothelial Carcinoma; BRCA: Breast invasive carcinoma; COAD: 
Colon adenocarcinoma; HNSC: Head and Neck squamous cell carcinoma; LUAD: 
Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; OVCA: Ovarian 
carcinoma).  
Figure 2 
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Figure 3 
Figure 3. Correlation plots for expression of representative genes and EMT scores of 
human tumors from TCGA datasets (BASAL: Basal-like breast cancer; BCLA: 
Bladder Urothelial Carcinoma; BRCA: Breast invasive carcinoma; COAD: Colon 
adenocarcinoma; HNSC: Head and Neck squamous cell carcinoma; LUAD: Lung 
adenocarcinoma; LUSC: Lung squamous cell carcinoma; OVCA: Ovarian 
carcinoma). 
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Figure 4 
Figure 4. Graph showing the fraction of genes from TCGA dataset analysis below 
the correlation value to EMT score. Purple line represents genes that are not 
associated with the ECM but still correlated with EMT gene signatures. ECM-related 
genes are represented by the red line with collagen-associated genes specifically 
denoted by green points. Collagen genes above a high correlation cutoff (r>0.5), as 
indicated by the red asterisks, were selected for further validation. Red arrows 
indicate qPCR validated collagen-associated genes that were consistently 
downregulated by miR-200, upregulated by Zeb1, and selected for further analyses. 
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Table 1. List of ECM-associated genes with strong, positive correlation (r>0.5) to 76-
gene EMT signature score of human tumors from TCGA datasets (BASAL: Basal-like 
breast cancer; BCLA: Bladder Urothelial Carcinoma; BRCA: Breast invasive carcinoma; 
COAD: Colon adenocarcinoma; HNSC: Head and Neck squamous cell carcinoma; 
LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; OVCA: Ovarian 
carcinoma). Spearman’s correlation and p-value significance are provided for each 
gene.
Gene Correlation P-value 
OLFML2B 0.77508867 0 
BNC2 0.75144666 0 
ZEB1 0.74211264 0 
TIMP2 0.74029499 0 
VIM 0.73904264 0 
FN1 0.72825134 0 
NID2 0.7237854 0 
ZEB2 0.72032535 0 
CALD1 0.71446639 0 
RECK 0.70482075 0 
FBN1 0.70115155 0 
ZNF521 0.69907582 0 
LAMA4 0.69839197 0 
FMNL3 0.69755876 0 
AXL 0.69564199 0 
ST3GAL2 0.69548142 0 
PDGFRB 0.69419038 0 
CDH11 0.68852288 0 
COL6A2 0.68809068 0 
LOXL3 0.68641251 0 
COL1A2 0.68476766 0 
SPARC 0.68381357 0 
ANXA6 0.68346918 0 
PMP22 0.68069249 0 
SH2B3 0.68030065 0 
ANGPTL2 0.67999649 0 
MSRB3 0.67685026 0 
COL6A1 0.67548305 0 
ADAM19 0.6747945 0 
VCAN 0.67221469 0 
OLFML1 0.67184317 0 
EMILIN1 0.67138064 0 
ARSB 0.67089987 0 
NAV3 0.67039979 0 
CNRIP1 0.66638559 0 
BICC1 0.66526175 0 
DACT1 0.66516554 0 
GPC6 0.66489744 0 
COL5A2 0.66363698 0 
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COL5A1 0.66338205 0 
AEBP1 0.66304922 0 
RASGRF2 0.66253018 0 
GLT8D2 0.66240907 0 
HLX 0.66164494 0 
SIRPA 0.66119581 0 
COL6A3 0.65892982 0 
MMP2 0.65889674 0 
IGDCC4 0.65876848 0 
WIPF1 0.65860069 0 
ENOX1 0.65831566 0 
GPR124 0.65746105 0 
DAB2 0.65628326 0 
THBS2 0.65404242 0 
KIAA1462 0.65379381 0 
GNG2 0.65211636 0 
TGFB1I1 0.65085971 0 
ADAMTS2 0.64958316 0 
FAM26E 0.64890295 0 
TGFB3 0.64839858 0 
ZCCHC24 0.64616239 0 
ADAMTS12 0.64516515 0 
FMOD 0.64411747 0 
CD248 0.64290082 0 
PLXDC2 0.64143974 0 
UNC5C 0.64064163 0 
POSTN 0.63946182 0 
PLEKHO2 0.63919276 0 
KIAA1949 0.63841105 0 
COL3A1 0.63651347 0 
TSHZ3 0.63629818 0 
STARD13 0.63616955 0 
CSGALNACT2 0.63560212 0 
FSTL1 0.6347633 0 
APBB2 0.63197225 0 
GFPT2 0.63002586 0 
LRRC32 0.62860966 0 
DCHS1 0.62855691 0 
GLIPR1 0.62822223 0 
ENTPD1 0.62470949 0 
CHN1 0.6246143 0 
RASA3 0.62393159 0 
ITGA4 0.62382507 0 
SGCD 0.62344533 0 
FAP 0.62286049 0 
FLI1 0.62256676 0 
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EMP3 0.62149209 0 
ETS1 0.62135446 0 
PCOLCE 0.61920804 0 
C13orf18 0.61894071 0 
GAS7 0.61809719 0 
INHBA 0.61721075 0 
CXCL12 0.61670548 0 
ECM2 0.61474174 0 
COL15A1 0.61469936 0 
BGN 0.61459953 0 
SULF1 0.61367607 0 
FGD5 0.61225814 0 
STARD8 0.61202985 0 
AKAP2 0.61179793 0 
TRPV2 0.61135787 0 
SCARF2 0.61127639 0 
FAM101B 0.61089855 0 
MMP16 0.60876548 0 
LHFPL2 0.60732466 0 
THY1 0.6067692 0 
EDNRA 0.60675019 0 
PDZRN3 0.6064567 0 
ASAM 0.60643947 0 
NAP1L3 0.60616964 0 
COL1A1 0.60560262 0 
PALM2.AKAP2 0.60447824 0 
PCDHGA12 0.6041466 0 
ISLR 0.60411733 0 
ENPP2 0.60398382 0 
ACTA2 0.60315228 0 
PCDH18 0.60262364 0 
RHOJ 0.60209399 0 
GNAI2 0.60162085 0 
SYDE1 0.60060704 0 
CPXM1 0.60044688 0 
PPAPDC3 0.59908974 0 
VCAM1 0.5988555 0 
FPR3 0.59857547 0 
DDR2 0.59836227 0 
ANTXR1 0.59832674 0 
F2R 0.59765524 0 
CEP170 0.59703612 0 
TIMP3 0.59563893 0 
ARHGAP31 0.59405935 0 
CTSK 0.59319061 0 
DOCK10 0.59295261 0 
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ZNF423 0.59242547 0 
HTRA1 0.59169298 0 
CRISPLD2 0.59162205 0 
EMILIN2 0.59116507 0 
PRKG1 0.59066862 0 
SERPING1 0.59062266 0 
ZNF469 0.58953083 0 
COL4A1 0.58892143 0 
PRRX1 0.58657604 0 
LOXL2 0.58642912 0 
VGLL3 0.58603346 0 
HRH2 0.5859803 0 
SGIP1 0.58589894 0 
FIBIN 0.58499253 0 
CCDC80 0.58434576 0 
HEG1 0.58380878 0 
FILIP1L 0.58335161 0 
HIC1 0.58316725 0 
IFFO1 0.58272338 0 
COL8A2 0.58229285 0 
NLRP3 0.58221179 0 
FAM180A 0.58127719 0 
DACT3 0.58071685 0 
SSPN 0.5807097 0 
MRC2 0.58058602 0 
LILRB2 0.58038402 0 
LIX1L 0.58034509 0 
VASH1 0.58031565 0 
COLEC12 0.57852232 0 
TNS3 0.57755578 0 
KCTD12 0.57751447 0 
CSF1R 0.57748032 0 
BMP2K 0.57736826 0 
PTGIR 0.57713461 0 
LRRC8C 0.57707852 0 
STK10 0.57636374 0 
KCNMB1 0.57632911 0 
PDGFC 0.57578105 0 
COL12A1 0.57540518 0 
NEXN 0.57527429 0 
FAM38B 0.57508039 0 
FCGR2A 0.57480353 0 
ZFPM2 0.57406712 0 
MMP14 0.5737316 0 
EPB41L2 0.57295245 0 
TLR4 0.57252759 0 
38 
 
FLJ10357 0.5721361 0 
CCDC88A 0.57193816 0 
MRVI1 0.57161564 0 
ENG 0.57068932 0 
LRRC15 0.57018244 0 
GAS1 0.56949604 0 
ADAM12 0.5690462 0 
IGSF21 0.56879705 0 
CD300C 0.5677861 0 
COL4A2 0.56701767 0 
FBLN2 0.56684995 0 
MXRA5 0.56673473 0 
CD93 0.56637394 0 
TMEM26 0.56621647 0 
LZTS1 0.56492096 0 
EFEMP2 0.56477457 0 
BTBD19 0.56468529 0 
CMTM3 0.56462085 0 
FNDC1 0.56424922 0 
CMKLR1 0.56413466 0 
C10orf72 0.56396836 0 
TNFSF4 0.56344551 0 
PDE1B 0.56255144 0 
SLAMF8 0.56189811 0 
CDK14 0.56107461 0 
EBF1 0.56101757 0 
TGFBI 0.56041968 0 
CD209 0.56023633 0 
C3AR1 0.55989301 0 
PRR16 0.55983782 0 
ISM1 0.55911821 0 
PREX1 0.55874676 0 
THBS1 0.55859721 0 
GYPC 0.5585835 0 
LRRC25 0.55847901 0 
CD163 0.55790287 0 
ANTXR2 0.55715334 0 
ITGB3 0.55687892 0 
PLXNC1 0.55521357 0 
WISP1 0.55499554 0 
GXYLT2 0.55496526 0 
SIRPB1 0.55485654 0 
ROR1 0.55471385 0 
TMEM200A 0.55411464 0 
ITGA1 0.55386978 0 
ARHGEF6 0.55359828 0 
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DSE 0.55321348 0 
LAMB1 0.55305099 0 
ADAMTS6 0.55302978 0 
MPP1 0.55270892 0 
EVC 0.55245465 0 
C5AR1 0.55187613 0 
MYLK 0.55159366 0 
DOCK2 0.55113667 0 
LILRA6 0.55086905 0 
CTHRC1 0.55080414 0 
SYT11 0.55074656 0 
CYTH4 0.54998791 0 
CD4 0.54818076 0 
PKD2 0.54805273 0 
NRP2 0.54762161 0 
SEMA6B 0.54723734 0 
ITGA5 0.54721087 0 
TMEM169 0.54689485 0 
MYADM 0.54620367 0 
CD86 0.54605186 0 
MAN1A1 0.54539591 0 
STX2 0.54521555 0 
PIK3CG 0.54421985 0 
CYSLTR2 0.54414433 0 
ODZ3 0.54376811 0 
JAM3 0.54337281 0 
FCGR2C 0.54293352 0 
MITF 0.54291993 0 
IL7R 0.54270399 0 
DCLK2 0.54243618 0 
RAB3IL1 0.54178822 0 
CCR1 0.54178447 0 
KIAA1755 0.5416801 0 
TNFAIP6 0.54152846 0 
CLIC4 0.54149622 0 
CD14 0.54117471 0 
LRRC17 0.54110479 0 
LPAR4 0.54109895 0 
PRICKLE1 0.54098701 0 
RUSC2 0.54091918 0 
ZYX 0.54087973 0 
S1PR3 0.54079324 0 
STAB1 0.54059643 0 
RAB8B 0.53999609 0 
LHFP 0.53993905 0 
C14orf49 0.53897834 0 
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PTRF 0.53881031 0 
NCKAP1L 0.53860348 0 
MRGPRF 0.53845203 0 
QKI 0.53777444 0 
MPEG1 0.53757906 0 
HAS2 0.53739011 0 
LILRB3 0.5373593 0 
NETO1 0.53734452 0 
ACVRL1 0.5372687 0 
CCIN 0.53690666 0 
APLNR 0.53663915 0 
XYLT1 0.53661847 0 
MFRP 0.5361926 0 
MAFB 0.53607529 0 
CTGF 0.53598762 0 
MAGEL2 0.53456384 0 
RUNX1T1 0.53435534 0 
LCP1 0.5330044 0 
C9orf110 0.53293681 0 
ALPK2 0.53286964 0 
ADAMTS5 0.53282857 0 
ENPP1 0.53270561 0 
TMEM204 0.53236228 0 
SLCO2B1 0.53222394 0 
BHLHE41 0.53176594 0 
DOK5 0.53115624 0 
FCGR3A 0.53109282 0 
PDGFRA 0.53062427 0 
SAMHD1 0.53041106 0 
RASGRP4 0.52972591 0 
LRCH1 0.52966404 0 
LCP2 0.52961135 0 
ITGAM 0.52892733 0 
GLIPR2 0.52853382 0 
CYBB 0.52829826 0 
SPON1 0.52819175 0 
CD80 0.52791029 0 
ITGA11 0.52754319 0 
COL5A3 0.52711254 0 
MYL9 0.52709389 0 
SLC8A1 0.5270471 0 
ABCA6 0.52675033 0 
LAIR1 0.52672267 0 
LOC399959 0.52671146 0 
DENND2A 0.52615231 0 
FAM70B 0.52585912 0 
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DOCK11 0.5258348 0 
RCSD1 0.52574283 0 
LOX 0.52544659 0 
PLXDC1 0.52497023 0 
SLA 0.52480561 0 
GIMAP4 0.52470005 0 
KIRREL 0.52446818 0 
HEPH 0.52431315 0 
LRP1 0.5242638 0 
PIK3R5 0.5241642 0 
NLRC4 0.52386314 0 
CD84 0.52382308 0 
KLHL4 0.52376455 0 
CSF2RB 0.52342629 0 
GPR176 0.52333796 0 
PABPC5 0.52325284 0 
GAL3ST4 0.52321702 0 
FERMT2 0.5230962 0 
LAPTM5 0.5230915 0 
RNASE6 0.52297437 0 
MRAS 0.52276397 0 
PDCD1LG2 0.52269757 0 
IL16 0.52245182 0 
F13A1 0.52235103 0 
SIGLEC9 0.52195907 0 
PILRA 0.52149361 0 
JPH2 0.52141839 0 
C13orf33 0.52104062 0 
NCF2 0.52093148 0 
C1R 0.52080357 0 
SIRPB2 0.52070153 0 
SLC7A7 0.52005929 0 
CACNA1C 0.5199663 0 
COL11A1 0.51975435 0 
CSMD2 0.51941365 0 
LGALS1 0.51889056 0 
CORIN 0.51799816 0 
PCDH12 0.51789659 0 
ACTN1 0.51772529 0 
PDLIM7 0.51658159 0 
GIMAP8 0.51657283 0 
FAM78A 0.51655948 0 
SHANK1 0.51618922 0 
TAGLN 0.51563263 0 
SSC5D 0.51539308 0 
GJD3 0.51508814 0 
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NOX4 0.5148434 0 
CLIP3 0.51458275 0 
ADARB1 0.51452833 0 
CXorf36 0.51439327 0 
CAMK1G 0.51391006 0 
CD200 0.51384175 0 
C1QTNF1 0.51362574 0 
PHLDB1 0.51356649 0 
FYB 0.51353884 0 
TLN1 0.51309967 0 
GPR84 0.51305586 0 
FAT4 0.51279157 0 
PIK3R6 0.5119378 0 
FPR1 0.51186574 0 
CCR8 0.51130164 0 
LILRB1 0.51055831 0 
GPR68 0.51050574 0 
CILP 0.51047117 0 
TBC1D1 0.51029801 0 
MAP3K3 0.51025289 0 
MXRA8 0.50993842 0 
VEGFC 0.50955409 0 
ASPN 0.50946003 0 
NFAM1 0.50925368 0 
TMEM119 0.50892472 0 
HTRA3 0.50889629 0 
CLEC11A 0.50842279 0 
GPX8 0.50831175 0 
SLIT2 0.50794894 0 
GAB3 0.50793862 0 
AP1S2 0.50754285 0 
ADAMTSL1 0.50706649 0 
BACE1 0.50657123 0 
ITGAV 0.50613737 0 
ADAMTS9 0.50594002 0 
GAS6 0.50592047 0 
FHL3 0.50578779 0 
FGFR1 0.50571179 0 
LPXN 0.50532377 0 
ELTD1 0.50523078 0 
LIMS1 0.50510842 0 
LATS2 0.5050326 0 
OSCAR 0.50488865 0 
GNA12 0.50487685 0 
SELPLG 0.50440782 0 
SLC1A3 0.50429708 0 
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SGK269 0.5042789 0 
SPI1 0.50416362 0 
JAZF1 0.50413489 0 
MFGE8 0.50385022 0 
KCNK13 0.50384933 0 
SLC36A1 0.50378346 0 
CYR61 0.50367254 0 
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Focusing this analysis on lung adenocarcinoma and squamous cell carcinoma samples 
with a high correlation cutoff, we delineated multiple collagen family and ECM-
associated genes that showed strong correlation with EMT (Figure 4). To validate 
which specific collagen genes are differentially regulated by miR-200 and ZEB1, we 
performed qPCR assays of each collagen and collagen-associated gene from Figure 4 
in a panel of human and murine epithelial and mesenchymal lung cancer cell lines with 
overexpression of ZEB1 or miR-200, respectively. Expression of miR-200 in 
mesenchymal murine and human lung cancer cells (H157 and 344SQ) consistently 
showed a decrease in mRNA levels for collagen type I, type III, as well as the collagen 
crosslinking enzymes LOX and LOXL2, which are indicated by red arrows in Figure 4 
(Figure 5). 
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Figure 6 
Figure 5 
Figure 5. qPCR analysis for relative expression of COL1A1, COL3A1, LOX, and 
LOXL2 in human H157 and murine 344SQ mesenchymal lung cancer cell lines with 
inducible and stable miR-200 expression, respectively. Asterisks (*) for qPCR data 
indicate significance value of p<0.01. 
Figure 6. qPCR analysis for relative expression of COL1A1, COL3A1, LOX, and 
LOXL2 in human H441 and murine 393P epithelial lung cancer cell lines with 
inducible and stable Zeb1 expression, respectively. Asterisks (*) for qPCR data 
indicate significance value of p<0.01. 
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Conversely, ZEB1 expression in epithelial cells (H441 and 393P) consistently displayed 
an increase in mRNA levels for these genes (Figure 6). Further induction of EMT in the 
metastatic 344SQ murine lung cancer cell line by TGF-β (33) drastically increased 
expression of the same collagen-associated genes as well (Figure 7). 
  
Figure 7 
Figure 7. qPCR analysis for relative expression of collagen-associated genes in 
344SQ cells treated with TGF-β for 7 days. 
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This relationship between ECM-associated gene expression and EMT is consistent 
with results from 3D culture experiments, which demonstrate that Zeb1-mediated 
mesenchymal lung cancer cell invasion is not only dependent upon extrinsic collagen 
interaction (33) (Figure 8), but requires additional crosslinking, maturation, and 
deposition of collagen fibers when cultured under low collagen concentrations (62) 
(Figure 9). Although several other collagen genes were correlated with EMT, 
expression of these genes either showed inconsistent correlation between miR-200 
and ZEB1 or had undetectable qPCR signals due to low basal levels of expression in 
the lung cancer cell lines tested (Figure 7 and Figure 10). 
  
48 
 
  
Figure 8. Left: Three-dimensional culture of 393P cells with constitutive Zeb1 or 
vector control expression in pure Matrigel or a 1:1 mixture of Matrigel and collagen. 
Right: Three-dimensional culture of H157 cells with inducible miR-200a/b or vector 
control in pure Matrigel or a 1:1 mixture of Matrigel and 1.5mg/ml collagen. Bright 
field microscopy images were captured at 4x magnification, scale bars represent 
200 µm. 
Figure 9 
Figure 8 
Figure 9. Second harmonic generation (SHG) images of Matrigel/collagen mixtures 
at 1.5 mg/ml or 3 mg/ml final collagen concentration. Linear fibers at 3 mg/ml 
concentration indicate crosslinked, mature collagen fibers. Lower concentrations of 
collagen do not exhibit this crosslinking. 
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Figure 10 
Figure 10. Top: qPCR analysis for relative expression of collagen-associated genes 
identified from TCGA dataset analysis in Figure 1B in mesenchymal human H157 
and murine 344SQ cells with inducible or stable miR-200 expression, respectively. 
Bottom: qPCR analysis for relative expression of collagen-associated genes in 
epithelial human H441 and murine 393P cells with inducible or stable Zeb1 
expression, respectively. 
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Metastatic lung tumors have increased LOX, LOXL2, collagen deposition and 
linearization, correlating with their EMT status 
Once we confirmed the correlation between EMT and collagen-associated gene 
expression in vitro, we next sought to verify this correlation in vivo. Analysis of primary 
lung tumors in KP mice capable of metastasis compared to non-metastatic KrasG12D 
mice revealed greater tumor areas presenting EMT patterns (based on Zeb1, E-
cadherin, and Vimentin levels), which correlated with increased total collagen, collagen 
type I/type III deposition, and LOX/LOXL2 expression (Figure 11). 
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Figure 11 
Figure 11. Hematoxylin and eosin (H&E), Masson’s trichrome, Zeb1, E-cadherin, 
Vimentin, collagen type I/type III, LOX, and LOXL2 immunohistochemical (IHC) 
stains, and second harmonics generation (SHG) microscopy of lung tumor tissues 
from non-metastatic KrasG12D and metastatic KrasG12D;p53R172H (KP) mice (n=5 
tissues per group). Upper right corner: Quantification of curvature ratio for individual 
collagen fibers (n=50 collagen fibers per sample) imaged by SHG microscopy of 
tumor tissues. Microscopy images were captured at 20x magnification, scale bars 
represent 50 µm. 
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Second harmonics generation (SHG) microscopy of collagen fibers in the tumor tissues 
confirmed the increase in collagen density and revealed increased collagen fiber 
linearization in the KP tumors (Figure 11). To validate that mesenchymal lung cancer 
cells were directly responsible for collagen deposition and fibrillar organization in 
primary tumors, we analyzed syngeneic tumors generated by subcutaneous injection of 
the non-metastatic 393P (epithelial) and highly metastatic 344SQ (mesenchymal) 
murine lung cancer cell lines in syngeneic wild type mice (33). Tissue stains confirmed 
the mesenchymal phenotype of 344SQ tumors (high nuclear Zeb1, low/mislocalized E-
cadherin, and high cytoplasmic vimentin) compared to 393P tumors (low/absent 
nuclear Zeb1, high/membranous E-cadherin, absent vimentin), correlating with an 
increase in collagen type I, type III, and LOXL2 expression but no change in LOX levels 
(Figure 12). SHG analysis also showed increased linear collagen fibers in the 
mesenchymal 344SQ tumors (Figure 12). Previous studies have shown that the 
collagen fiber linearization is dependent on collagen crosslinking by LOX enzymes (62, 
98, 99). Our findings suggest that up-regulation of collagen and LOX/LOXL2 in 
mesenchymal lung cancer cells results in increased collagen deposition and 
organization in the tumor microenvironment. Because secreted LOX and LOXL2 are 
potential therapeutic targets (80) that have been implicated as drivers of metastasis in 
various cancer types (77, 78, 98-100), we sought to further test their mechanistic role in 
metastasis. 
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Figure 12 
Figure 12. Staining and SHG microscopy of primary syngeneic tumor tissues 
generated by subcutaneous injection of non-metastatic 393P and metastatic 344SQ 
murine lung cancer cell lines in syngeneic mice (n=10 tumors per group). Upper right 
corner: Quantification of curvature ratio for individual collagen fibers (n=50 collagen 
fibers per sample) imaged by SHG microscopy of tumor tissues. Microscopy images 
were captured at 20x magnification, scale bars represent 50 µm. 
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LOX and LOXL2 are directly regulated by miR-200 and ZEB1, respectively 
Since our previous studies have shown that the ZEB1/miR-200 axis is critical in 
regulating EMT and metastasis (33, 48), we wanted to determine if LOX and LOXL2 
expression were regulated by this EMT program. We first evaluated the protein levels 
of LOX and LOXL2 in the panel of murine and human lung cancer cell lines that we 
previously characterized (33, 48, 53, 89, 91) and observed higher levels of LOX and 
LOXL2 in mesenchymal cell lines with higher mesenchymal marker expression (Figure 
13 – 16). Snail1 does not associate with the EMT status or LOX/LOXL2 expression in 
these cells, which is consistent with our previous findings (33, 48) that EMT in this 
system is Zeb1-dependent (Figure 13). Although collagen I mRNA levels were higher 
in mesenchymal cells, collagen III expression did not significantly change between cell 
lines (Figure 14). Analyzing the conditioned media from our murine cell line panel 
revealed increased secreted LOXL2 protein from mesenchymal cells (Figure 13) and 
demonstrated active LOXL2 enzymatic function by Amplex Red assays (101) (Figure 
17). Interestingly, we were unable to detect secreted LOX in the conditioned media 
from any of the cell lines (Figure 13). Additional analysis of miR-200 and LOX/LOXL2 
gene expression confirmed lower miR-200c levels in mesenchymal cell lines and 
showed a strong, inverse correlation to LOX and LOXL2 mRNA levels (Figure 18). 
Forced expression of ZEB1 in epithelial murine and human cell lines induced EMT at 
the molecular level and led to an increase in LOX and LOXL2 protein levels (Figure 18 
– 21). Ectopic miR-200 expression or siRNA-mediated Zeb1 knockdown in 
mesenchymal cells had the contrasting effect (Figure 19, Figure 20, and Figure 22). 
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Figure 14 
Figure 13 Figure 14. qPCR analysis of relative expression of collagen genes Col1a1 and 
Col3a1 in murine lung cancer cell line panel. 
Figure 13. Top: Western blot analysis of Zeb1, Snail1, N-cadherin, Vimentin, LOX, 
LOXL2, and β-actin (loading control) in a panel of epithelial or mesenchymal murine 
KP lung cancer cell lines. Bottom: Western blot of secreted LOX and LOXL2 in 
conditioned media of murine panel cell lines. 
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Figure 15 
Figure 16 
Figure 15. Western blot analysis of Zeb1, LOX, LOXL2, and β-actin in a panel of 
epithelial or mesenchymal human lung cancer cell lines. 
Figure 16. qPCR analysis of relative Zeb1, LOX, and LOXL2 expression in the 
panel of epithelial or mesenchymal human lung cancer cell lines from Figure 15. 
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Figure 17 
Figure 17. Amplex Red assay to determine LOX/LOXL2 enzymatic activity in 
conditioned media of murine cell line panel. (*): p<0.05 and (**): p<0.01. 
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Figure 19 
Figure 19. Western blot analysis of Zeb1, LOX, LOXL2, and β-actin in epithelial 
393P and mesenchymal 344SQ cell lines with constitutive Zeb1 or miR-200a/b/429 
expression, respectively. 
Figure 18. Cluster plots of normalized miR-200c and LOX or LOXL2 mRNA levels in 
epithelial and mesenchymal murine lung cancer cell lines. 393P-Zeb1 and 344SQ-
miR200 cells have also been included in the analysis. Data points represent mean ± 
SD (n = 3 samples). Spearman’s rank correlation used for co-expression analysis. 
Figure 18 
59 
 
  
Figure 21 
Figure 20 
Figure 21. Left: Western blot analysis of Zeb1, LOX, LOXL2, and β-actin in epithelial 
H441 cells with doxycycline inducible Zeb1 over a 5-day time course. Right: Western 
blot of Zeb1, E-cadherin, N-cadherin, Vimentin, and β-actin in H441 cells with 
doxycycline inducible Zeb1. 
Figure 20. Left: Western blot analysis of Zeb1, E-cadherin, N-cadherin, LOX, 
LOXL2, and β-actin in 344SQ cells after 48hrs of Zeb1 knockdown by siRNA. Right: 
Western blot of EMT markers and LOX/LOXL2 in 307P cells after transient 
overexpression of Zeb1. 
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Figure 22 
Figure 22. Western blot analysis of Zeb1, LOX, and LOXL2, and β-actin in 
mesenchymal H157 cells with doxycycline inducible miR-200. 
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Due to the strong correlation between LOX, LOXL2, and the ZEB1/miR-200 axis, we 
proceeded to test whether these two enzymes were directly regulated by ZEB1 or miR-
200. Evaluating potential microRNA binding sites in the 3’-untranslated region (UTR) of 
LOX using the TargetScan (www.targetscan.org) algorithm revealed one potential miR-
200a and two potential miR-200b/c/429 seed sequences. Luciferase reporter assays 
with a cloned LOX 3’-UTR showed significant repression in luciferin signal in the 
presence of miR-200b/c but no repression with miR-200a (Figure 23), which was 
further validated through introduction of miR-200b/c binding site mutations for each site 
individually or in combination. These findings were consistent with algorithm predictions 
that showed the first miR-200b site as having strong sequence binding while the miR-
200a and second miR-200b sites had weaker complementation (Figure 24). Although 
LOXL2 has no predicted miR-200 binding sites, which we verified by 3’-UTR luciferase 
reporter assays (Figure 24 – 25), the promoter region contains several ZEB1 and 
ETS1 regulatory sites predicted by the JASPER transcription factor binding database 
(http://jaspar.genereg.net/), which are known to drive transcriptional activity in certain 
contexts (60, 102, 103). 
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Figure 23 
Figure 23. Top: Schematic of luciferase reporter constructs for wild-type (WT) 
mouse LOX-3ʹUTR and mutated potential miR-200b/c binding sites. Bottom: Relative 
luciferase activity of LOX-3’UTR reporter constructs above, co-transfected with non-
targeting control miRNA, miR-200a, miR-200b, or miR-200c precursors in 344SQ 
cells. Three experimental replicates were performed with three technical replicates 
per experiment. 
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Figure 24 
Figure 24. TargetScan prediction of strongest potential microRNA binding sites on 
LOX, Col1a1, Col3a1, and LOXL2 3’-UTR. 
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Figure 25 
Figure 25. Top: Schematic of LOXL2 3’-UTR showing no predicted miR-200 binding 
sites. Bottom: LOXL2 3’-UTR luciferase reporter assay following co-expression with 
miR-200a, 200b, or 200c. 
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Luciferase reporter assays with the wild-type LOXL2 promoter region confirmed 
transcriptional regulation by ZEB1, which was verified by introduction of mutations into 
each of the ZEB1 binding sites individually and in combination. We further confirmed 
direct binding of ZEB1 to the endogenous LOXL2 promoter region by ZEB1 chromatin 
immunoprecipitation (ChIP) assays in multiple epithelial and mesenchymal cell lines 
(Figure 26). The collagen I (COL1A1) and collagen III (COL3A1) genes did not show 
any predicted miR-200 binding sites in their 3’-UTR (Figure 24) nor any potential Zeb1 
binding sites in their promoters (data not shown), suggesting an indirect mechanism of 
regulation. 
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Figure 26 
Figure 26. Top: Schematic of luciferase reporter constructs for mouse LOXL2 
promoter region containing predicted Zeb1 and Ets1 binding sites. Mutations of 
potential Zeb1 binding sites indicated with red X and location of qPCR primers to 
amplify the region containing potential Zeb1 binding sites indicated by black arrows. 
Bottom-Left: Relative luciferase activity of LOXL2 reporter constructs above 
transfected into epithelial 393P cells with vector control or Zeb1 expression. Bottom-
Right: Fold enrichment by qPCR analysis of LOXL2 promoter segments containing 
potential Zeb1 binding sites after chromatin immunoprecipitation in 393P-pcDNA 
vector control and 393P-Zeb1 cells, using Zeb1 antibody or mock IgG control 
antibody. 
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LOX enzymatic function is necessary for lung cancer cell migration and invasion 
We next wanted to assess the functional relevance of LOX and LOXL2 in promoting 
lung cancer cell migration and invasion. Inhibition of pan-LOX enzymatic activity with β-
aminopropionitrile (BAPN) significantly reduced enzymatic activity in conditioned media 
(Figure 27) as well as Transwell migration and collagen invasion of mesenchymal 
murine 344SQ, 393P-ZEB1, and human H157 cells, but with no significant change in 
invasion through laminin-rich Matrigel (Figure 28). BAPN treatment of 393P-ZEB1 cells 
significantly reduced formation of invasive structures in 3D Matrigel/collagen I (Figure 
29) and reduced invasion of 344SQ cells through Matrigel alone upon TGF-β induction 
(Figure 30). Because LOX enzymes require copper as a co-factor, we also utilized the 
copper chelator D-Penicillamine (D-Pen) to inhibit LOX enzyme function and observed 
a significant reduction in 393P-ZEB1 2D migration/invasion in Transwell assays or 3D 
Matrigel/collagen I assays (Figure 31). We observed no adverse effects of the 
inhibitors on cell proliferation and viability (Figure 32). We next evaluated the effects of 
BAPN and D-Pen treatment on metastasis of 344SQ cells in syngeneic mice in vivo. 
Mice that received either inhibitor did not show a significant change in tumor size or 
metastatic lesions (Figure 33 – 34). Interestingly, analysis of collagen fibers by SHG 
revealed increased linearized collagen in primary tumor tissues (Figure 35), which 
suggests that the inhibitors either do not effectively reach the primary tumors or 
produced off-target effects. These results are consistent with several studies 
corroborating the inconsistency and ineffectiveness of chemical LOX inhibitors in vivo 
(80, 98, 104-107). 
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Figure 27 
Figure 28 
Figure 28. Left: Transwell migration and invasion through collagen for 344SQ cells 
treated with 500 µM BAPN. Middle: Transwell migration and invasion through 
Matrigel and collagen for 393P-Zeb1 cells treated with 500 µM BAPN compared to 
untreated H2O control. Asterisks (*) indicate significance value of p<0.01. Right: 
Transwell migration and invasion through Matrigel and collagen for H157 cells 
treated with 500 µM BAPN. 
Figure 27. Amplex Red assay to determine LOX/LOXL2 enzymatic activity in 
conditioned media of 344SQ and 393P-Zeb1 cells with or without 500 µM BAPN 
treatment. 
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Figure 29 
Figure 30 
Figure 31 
Figure 30. Left: Bright field microscopy images of three-dimensional culture of 
344SQ cells co-treated with 5 ng/ml TGF-β and 5 mM BAPN. Right: Quantification of 
fraction of 3D structures that displayed invasive phenotype (n=50 structures per 
treatment group). Microscopy images were captured at 4x magnification, scale bars 
represent 200 µm. 
Figure 31. Left: Transwell migration and invasion through collagen for 344SQ cells 
treated with 300 µM D-Penicillamine (D-Pen). Right: 393P cells with constitutive 
Zeb1 expression cultured in a 3D matrix consisting of 1.5 mg/ml collagen/Matrigel 
mixture for 7 days, treated with 300 µM D-Pen. Quantification of fraction of invasive 
structures in 3D culture assays to the right (n = 50 structures counted per condition). 
Microscopy images were captured at 4x magnification, scale bars represent 200 µm. 
Figure 29. 393P cells with constitutive Zeb1 expression cultured in a 3D matrix 
consisting of 1.5 mg/ml collagen/Matrigel mixture for 7 days, treated with 500 µM 
BAPN. 
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Figure 32 
Figure 33 
Figure 34 
Figure 32. Left: WST-1 cell proliferation and viability assay for 344SQ and 393P-
Zeb1 cells treated with 500 µM BAPN. Right: WST-1 cell proliferation and viability 
assay for 344SQ cells treated with 300 µM D-Pen. 
Figure 33. Left: Primary subcutaneous tumor volume of 344SQ cells injected in 
syngeneic mice with daily intraperitoneal (I.P.) administration of BAPN. Right: 
Quantification of lung metastatic nodules after treatment with BAPN. 
Figure 34. Left: Primary subcutaneous tumor volume of 344SQ cells injected in 
syngeneic mice with daily I.P. administration of D-Pen. Right: Quantification of lung 
metastatic nodules after treatment with D-Pen. 
71 
 
  
Figure 35 
Figure 35. Left: SHG microscopy images of primary subcutaneous tumor tissues 
from experimental mice in Figure 33. Right: Quantification of curvature ratio for 
individual collagen fibers from SHG microscopy images generated on the left. 
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LOXL2 is necessary for collagen deposition, crosslinking and tumor cell 
metastasis 
Given the inconsistent results with LOX chemical inhibitors in vivo, we next employed a 
genetic approach to study the role of LOX and LOXL2 in driving invasion and 
metastasis. Stable shRNA-mediated knockdown of LOX in metastatic 344SQ cells 
significantly decreased migration and invasion through Transwell Matrigel or collagen I 
chambers (Figure 36), but did not have a significant effect on primary tumor growth or 
metastasis in vivo (Figure 37). In contrast, LOXL2 knockdown decreased invasion only 
through collagen I and significantly suppressed metastasis in vivo (Figure 38 – 39). 
LOX and LOXL2 knockdown in a different metastatic KP cell line, 344LN, produced 
comparable results both in vitro and in vivo, with LOXL2 knockdown cells exhibiting 
diminished metastatic lung nodules that were also markedly smaller in size (Figure 40 - 
42). Analysis of the conditioned media showed a significant decrease in enzymatic 
activity upon LOXL2 knockdown but an insignificant reduction when LOX was knocked 
down (Figure 43). 
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Figure 36 
Figure 37 
Figure 36. Left: Western blot of LOX protein levels after stable shRNA knockdown in 
344SQ cells. Right: Transwell migration and invasion through Matrigel and collagen 
for 344SQ cells with LOX knockdown. 
Figure 37. Left: Primary subcutaneous tumor volume of 344SQ cells with stable 
LOX knockdown injected into syngeneic mice. Right: Quantification of lung 
metastatic nodules from 344SQ cells with stable LOX knockdown. 
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Figure 38 
Figure 39 
Figure 38. Left: Western blot of LOXL2 protein levels after stable shRNA 
knockdown in 344SQ cells. Right: Transwell migration and invasion through Matrigel 
and collagen for 344SQ cells with LOXL2 knockdown. 
Figure 39. Left: Primary subcutaneous tumor volume of 344SQ cells with stable 
LOXL2 knockdown injected in syngeneic wild type mice. Right: Quantification of lung 
metastatic surface nodules after subcutaneous injection of 344SQ cells with stable 
LOXL2 knockdown in syngeneic wild type mice. 
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Figure 40 
Figure 41 
Figure 40. Western blot of LOX and LOXL2 protein levels after stable shRNA 
knockdown in 344LN cells. 
Figure 41. Migration, Matrigel invasion, and collagen invasion of 344LN cells after 
stable LOX and LOXL2 knockdown. 
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Figure 42 
Figure 43 
Figure 42. Left: Primary subcutaneous tumor volume of 344LN cells with stable LOX 
and LOXL2 knockdown injected in syngeneic wild type mice. Right: Quantification of 
lung metastatic nodules from 344LN cells with stable LOX and LOXL2 knockdown. 
Bottom: Whole tissue images and H&E sections of lungs collected from mice with 
subcutaneous injection of 344LN cells after stable LOX and LOXL2 knockdown. 
Figure 43. Amplex Red assay for H2O2 concentration in conditioned media of 
344SQ cells with stable LOXL2 or LOX knockdown. 
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Developmentally, extracellular LOX enzymes are required for insoluble collagen 
deposition (66, 79, 108). Therefore, we analyzed the primary syngeneic tumors from 
our LOX and LOXL2 knockdown experiments for collagen deposition and 
reorganization. Upon LOXL2 knockdown, both collagen type I and type III deposition 
were significantly reduced, along with a significant decrease in linear collagen fibers 
(Figure 44 – 45). Consistently, the decrease in tumor collagen content and 
organization was followed by a decrease in tissue stiffness (Figure 46). In contrast, 
LOX knockdown had no effect on the deposition of either collagen isoform (Figure 47), 
which is consistent with results from our enzymatic activity assays. LOXL2 knockdown 
did not alter collagen I and III gene expression (Figure 48), which suggests that the 
decrease in collagen deposition in vivo is due to lack of crosslinking and maturation. To 
further verify that LOXL2 is involved in collagen crosslinking and linearization, we 
visualized collagen fibers by scanning electron microscopy after culture of 344SQ-
shLOXL2 cells in collagen I gels. Fiber alignment algorithms showed a significant 
reduction in average linear collagen fibers when LOXL2 was knocked down compared 
to the vector control (Figure 49). To definitively confirm that LOXL2 is responsible for 
crosslinked collagen in the tumor tissues, we performed mass spectrometry analysis on 
the lysine and hydroxylysine residues of collagen (109) that form when two or three 
collagen molecules form covalent bonds on their lysine residues during crosslinking 
(DHLNL, HLNL, d-Pyr, and HHMD) (71). Knockdown of LOXL2 significantly reduced 
the ratio of crosslinked lysine residues in the tumor tissues compared to vector 
controls, directly establishing the role of LOXL2 in crosslinking collagen in vivo (Figure 
50). 
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Figure 44 
Figure 44. H&E and IHC stains of LOXL2, collagen type I, and type III along with 
SHG microscopy of primary syngeneic tumor tissues from 344SQ cells with either a 
vector control or stable LOXL2 knockdown. Microscopy images were captured at 
20x magnification, scale bars represent 50 µm. 
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Figure 45 
  
Figure 45. Quantification of curvature ratio for individual collagen fibers imaged by 
SHG microscopy of tumor tissues from Figure 43. 
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Figure 46 
Figure 46. Mechanical stiffness measurements of tumor tissues from in Figure 43. 
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Figure 47 
Figure 48 
Figure 47. H&E, LOX, collagen type I/type III IHC stains, and SHG microscopy 
images of subcutaneous primary tumor tissues from 344SQ cells with stable LOX 
knockdown in syngeneic mice. Microscopy images were captured at 20x 
magnification, scale bars represent 50 µm. 
Figure 48. qPCR analysis of relative COL1A1 and COL3A1 mRNA levels after 
stable LOXL2 knockdown in 344SQ cells. 
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Figure 49 
Figure 49. Right: Scanning electron microscopy (SEM) images of 2 mg/ml collagen 
gels after culturing 344SQ cells with or without LOXL2 knockdown. Images were 
viewed at 10kV and images were captured at 10kX magnification. Scale bars, 5 µm 
(n = 3 collagen gel molds per cell line). Left: Alignment analysis of collagen fibers to 
determine linearity and organization of collagen fibers as described in Methods 
section. The Kuiper test was used to test for differences in alignment between the 
sets of decimated data with significance as indicated. 
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Figure 50 
Figure 50. Ratio of the number of molecules of crosslinked lysine residues from 
collagen versus total collagen molecules in 344Q tumors with stable LOXL2 
knockdown. Molecules of crosslinked lysine residues were analyzed by mass spec. 
Mass spec analysis performed by the laboratory of Mitsuo Yamauchi from University 
of North Carolina. 
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LOX and LOXL2 ectopic expression is not sufficient for epithelial cancer cell 
migration and invasion 
Next, we took the converse approach and ectopically expressed LOX and LOXL2 in 
epithelial, non-metastatic 393P cells using a doxycycline-inducible pTRIPz vector. LOX 
and LOXL2 were either tagged or untagged with GFP at the N-terminus region. 
Western blots of LOX/LOXL2 induced cells confirmed proper expression of the desired 
proteins. However, only the untagged version of LOXL2 was detectable in the 
conditioned media, suggesting that the GFP interferes with the signaling peptide at the 
N-terminus region. GFP-tagged and untagged LOX was undetectable in the 
conditioned media (Figure 51). This finding was also verified by enzymatic assays of 
the conditioned media of the overexpression cell lines, which showed that only the 
LOXL2 expressing cells had extracellular enzymatic activity (Figure 52). There was no 
significant difference in Transwell migration and invasion with induced LOX expressed 
(Figure 53). However, when LOXL2 expression was induced, there was only a 
significant increase in invasion when extrinsic collagen was coated on the Transwell 
inserts (Figure 53). LOX and LOXL2 were also ectopically expressed in epithelial 
murine 307P and human H322 cells, which have low endogenous levels of LOX/LOXL2 
(Figure 13 and Figure 15). Similar to 393P cells, we observed a significant, robust 
increase in invasion only through collagen coated Transwells when LOXL2 was 
expressed in 307P and H322 cells (Figure 54 and 55). Since collagen gene expression 
is unaltered when LOX or LOXL2 is overexpressed (Figure 56), this suggests that 
coordinate collagen expression by mesenchymal cells is also necessary to drive 
invasion and metastasis and that LOX or LOXL2 alone is not sufficient to promote 
migration and invasion.  
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Figure 51 
Figure 51. Left: Western blot of LOX, GFP, and β-actin in 393P cells expressing 
doxycycline (Dox) inducible GFP, LOX with GFP tagged to the N-terminus (GFP-
LOX), or untagged LOX. Right: Western blot of LOXL2, GFP, and β-actin in 393P 
cells expressing Doxycycline inducible GFP, LOXL2 with GFP tagged to the N-
terminus (GFP-LOXL2), or untagged LOXL2. 
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Figure 52 
Figure 53 
Figure 52. Left: Amplex Red assay of conditioned media from 393P cells with Dox 
induced GFP, GFP-LOX, or LOX. Right: Amplex Red assay of conditioned media 
from 393P cells with Dox induced GFP or untagged LOXL2. 
Figure 53. Left: Transwell migration and invasion through Matrigel and collagen for 
393P cells expressing inducible GFP or untagged LOX. Right: Transwell migration 
and invasion through Matrigel and collagen for 393P cells expressing inducible GFP 
or untagged LOXL2.  
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Figure 54. Left: Western blot of LOX, LOXL2, and β-actin in epithelial 307P cells 
transiently transfected with LOX or LOXL2. Right: Western blot of LOX, LOXL2, and 
β-actin in human epithelial H322 cells transiently transfected with LOX or LOXL2. 
Figure 54 
Figure 55 Figure 55. Left: Transwell migration, Matrigel invasion, and collagen invasion of 
307P cells transiently transfected with LOX and LOXL2. Right: Transwell migration, 
Matrigel invasion, and collagen invasion of H322 cells transiently transfected with 
LOX or LOXL2. 
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Figure 56 
Figure 56. qPCR analysis of COL1A1 and COL3A1 in 393P cells expressing Dox 
induced GFP, LOX, or LOXL2. 
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LOXL2-mediated collagen deposition induces FAK/Src signaling in vitro and in 
vivo 
Our group recently demonstrated that activation of the integrin β1/FAK/Src signaling 
pathway through collagen type I interaction is necessary for lung cancer invasion and 
metastasis (58). Since EMT causes lung cancer cells to deposit insoluble collagen by 
LOXL2 crosslinking, we investigated the potential autocrine effect that LOXL2 has on 
FAK/Src signaling. Immunofluorescent staining for activated phosphorylated FAK 
(Y861) and Src (Y416) showed that enzymatic inhibition or knockdown of LOXL2 
decreased focal adhesion formation and FAK/Src signaling after TGF-β-mediated 
stimulation of 344SQ cells (Figure 57 and 58). Western blotting confirmed the 
suppression of signaling by LOXL2 KD or inhibition and further emphasized that 
knockdown of LOX does not produce the same effect (Figure 59). Further analysis of 
primary syngeneic tumors with LOXL2 knockdown (Figure 44) by IHC staining 
revealed a decrease in activated FAK and Src versus control tumors (Figure 60), 
correlating with the decrease in collagen type I and type III deposition in the tumors 
(Figure 44). Collectively, our data supports a model in which ZEB1-driven 
mesenchymal lung cancer cells deposit collagen in the tumor microenvironment 
through LOXL2 crosslinking, which further activates the integrin/FAK/Src signaling 
pathway in the cancer cells, leading to invasion and metastasis (Figure 61). 
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Figure 57 
Figure 58 
Figure 57. Left: Immunofluorescent staining of p-FAKY861 and p-SrcY416 (green dots) 
in 344SQ cells treated with 5 ng/ml TGF-β for 48 hours in the presence or absence 
of 500 µM BAPN. Right: Quantification of p-FAKY861 and p-SrcY416 signal per cell 
from immunofluorescent stains. 
Figure 58. Left: Immunofluorescent staining of p-FAKY861, p-SrcY416 (green dots), 
and β-catenin (red) in 344SQ cells after stable shRNA knockdown of LOXL2. β-
catenin used as a marker to identify cell membrane. Right: Quantification of p-
FAKY861 and p-SrcY416 signal per cell from immunofluorescent stains. 
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Figure 59 Figure 59. Western blot of p-FAKY861, total FAK, p-SrcY416, and total Src in 344SQ 
cells ± 5 ng/ml TGF-β treatment for 48 hours in the presence of 500 µM BAPN, with 
stable LOX or LOXL2 knockdown. 
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Figure 60 Figure 60. H&E and IHC stains of p-FAKY861 and p-SrcY416 of primary tumor tissues 
from subcutaneous injection of 344SQ cells with stable LOXL2 knockdown in 
syngeneic wild type mice. Microscopy images captured at 20x magnification, scale 
bars represent 50 µm. 
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Figure 61 Figure 61. Proposed model demonstrating Zeb1 regulation of collagen deposition in 
the tumor microenvironment through LOXL2 crosslinking and stabilization, activating 
the Integrin β1/FAK/Src signaling pathway in an autocrine manner leading to 
invasion and metastasis. 
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Increased collagen, LOX, and LOXL2 expression predicts poor prognosis among 
patients with lung adenocarcinoma 
Based upon these findings, we wanted to determine the prognostic value of the LOX 
and collagen proteins in predicting lung cancer patient survival and how their 
expression correlates with Zeb1 in human tumors. Pathologic assessment of stromal 
collagen I and III expression by IHC staining in a cohort of lung cancer specimens 
(n=490) revealed increased levels in lung adenocarcinoma (ACC) versus squamous 
cell carcinoma (SCC) samples (Figure 62 – 64), but no statistically significant 
correlation to pathologic stage or patient outcome (Figure 65). However, cytoplasmic 
scoring of collagen type I levels revealed greater amounts in poorly differentiated 
tumors of all histologic subtypes (Figure 66), consistent with our findings correlating 
collagen expression with EMT. Although we observed a trend toward higher collagen 
levels in late-stage adenocarcinomas and in patients with poorer outcomes (Figure 65 
and 67), the changes were statistically insignificant due to the relatively small sample 
size of late-stage tumors. Collagen type III did not display strong cytoplasmic staining in 
tumor tissues. To determine if Zeb1 correlated with collagen expression, we scored 
Zeb1 IHC stains specifically in the nuclei of tumor cells from the same cohort of tissue 
microarray specimens (Figure 62). Although Zeb1 did not show a significant difference 
between tumor differentiation grades (Figure 68), there was an increase in expression 
in patients with SCC compared to ACC (Figure 69). Zeb1 expression H-scores 
correlated moderately, but significantly with collagen I H-scores across all tumor 
histologic subtypes. However, when the samples were stratified by ACC and SCC 
histology, we observed an increased significant correlation between Zeb1 and collagen 
I expression in ACC patients (Figure 70) but no significant correlation in patients with 
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SCC (Figure 71). Zeb1 scores did not significantly correlate with stromal collagen I or 
III (Figure 72) nor did it correlate with patient outcome or pathological stage (data not 
shown). 
 Although we tested multiple antibodies for each, we were unable to analyze LOX 
and LOXL2 levels in the human specimens by IHC because none of the antibodies 
produced staining of clinically acceptable quality for scoring. To circumvent these 
issues, we performed Kaplan-Meier analyses using mRNA profiling from a large 
compendium of lung adenocarcinoma patients (n=1,586), which revealed decreased 
overall survival in patients whose tumors expressed elevated levels of collagen type I, 
type III, LOX, or LOXL2 (Figure 73). This decrease in patient survival with high LOXL2 
expression has also been previously observed in patients with lung SCC (110). 
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Figure 62 Figure 62. Well differentiated and poorly differentiated human lung adenocarcinoma tissue sections IHC stained for collagen type I, collagen type III, and Zeb1. Scale 
bars, 200 µm. 
97 
 
  
Figure 63 Figure 63. Positive and negative control tissues for collagen I, collagen III, and Zeb1 
IHC staining. Human skin tissues were used as positive and negative controls for 
collagen antibodies. Scale bars, 200 µm. 
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Figure 64 
Figure 65 
Figure 65. Left: Percent stromal area of collagen type I and type III expression in 
patients with lung cancer comparing different pathological stages. Middle: Percent 
stromal area of collagen type I and type III expression in patients with lung cancer 
comparing patient outcome. Right: Average final cytoplasmic H-score of collagen 
type I staining in patients with lung adenocarcinoma comparing patient outcome. 
Figure 64. Percent stromal area of tumor tissues with collagen type I or type III 
expression in patients with lung adenocarcinoma (ACC) or squamous cell carcinoma 
(SCC). 
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Figure 66 Figure 6. Average final cytoplasmic H-score of collagen type I expression in lung 
adenocarcinomas of different grades. 
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Figure 67 Figure 67. Average final cytoplasmic H-score of collagen type I staining in patients 
with lung adenocarcinomas of different pathologic stages.  
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Figure 68 Figure 68. Average final nuclear H-score of Zeb1 staining in lung cancer patients 
comparing different tumor grades. 
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Figure 69 Figure 69. Average final nuclear H-score of Zeb1 in tumor cells of ADC or SCC 
specimens. 
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Figure 70 Figure 70. Left: Cluster plot analysis of Spearman’s rank correlation between Zeb1 
and collagen I H-score in both ADC and SCC specimens. Right: Cluster plot 
analysis of Spearman’s rank correlation between Zeb1 and collagen I H-score in 
ADC samples. 
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Figure 71 Figure 71. Cluster plot analysis of Spearman’s rank correlation between Zeb1 and 
collagen I H-score in SCC patient tissues. 
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Figure 72 
Figure 73 
Figure 72. Left: Cluster plot analysis of Spearman’s rank correlation between Zeb1 
and collagen I stromal area expression. Right: Cluster plot analysis of Spearman’s 
rank correlation between Zeb1 and collagen III stromal area expression. 
Figure 73. Kaplan-Meier survival analysis by log-rank significance test of COL1A1, 
COL3A1, LOX, and LOXL2 mRNA expression levels versus overall lung cancer 
patient survival from a compendium expression dataset of 1,586 lung 
adenocarcinoma cases. P-values by log-rank test. 
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Project 2: Epithelial-to-Mesenchymal Transition promotes MEK inhibitor 
resistance in KRAS mutant lung cancers through suppression of IL17rd 
 
Epithelial lung cancer cells exhibit increased MAPK signaling and dependency 
for tumor growth 
To identify therapeutically targetable genes essential for tumor formation and growth in 
epithelial and mesenchymal KRAS mutant tumors, we utilized a previously developed 
in vivo loss-of-function screen approach with barcoded, pooled shRNA libraries (97) 
targeting approximately 200 genes that have FDA approved pharmacological inhibitors 
(FDAome). The shRNA library was transduced into representative epithelial (393P) and 
mesenchymal (344P) Kras and p53 mutant murine lung cancer cell lines derived from 
the KP mouse model (33) and implanted subcutaneously in nude mice or cultured in 
vitro (Figure 74). Tumors were harvested, shRNA barcodes were quantified by deep 
sequencing, referenced with the respective in vitro cell population, and the phenotypic 
impact of gene knockdown was inferred by the redundant shRNA activity (RSA) 
algorithm (111, 112), where lower rank of the shRNA barcodes signified dropout from 
the population and greater dependency of the gene for tumorigenesis (Table 2). 
Comparison of the results from the two models revealed that epithelial 393P tumors 
were more reliant on MAPK genes for in vitro and in vivo growth, while mesenchymal 
344P tumor growth was independent of MAPK signaling molecules, despite both cell 
lines possessing an activating KrasG12D mutation (Figure 75). 
 Complementing the in vivo shRNA screen, we sought to elucidate the specific 
differences in signaling patterns between epithelial and mesenchymal lung cancer cells 
that potentially confer MEK inhibitor resistance. Using reverse phase protein array 
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(RPPA) to analyze changes in cell signaling proteins in a high throughput manner (113, 
114), we screened a panel of previously characterized (33, 48) epithelial and 
mesenchymal murine/human lung cancer cell lines expressing Zeb1 or miR-200, 
respectively, and observed an increase in phosphorylated Mek/Erk proteins in epithelial 
cells (Figure 76 and 77). Validation of the RPPA findings by Western blotting in a 
representative panel of Ras mutant human NSCLC cell lines showed higher levels of 
endogenous MAPK activity (p-MEK & p-ERK) in epithelial cell lines as characterized by 
the EMT markers Zeb1, E-cadherin, and Vimentin (Figure 78). Additionally, modulation 
of the EMT status through induced miR-200 expression in mesenchymal cells 
increased p-Mek/p-Erk levels in a time-dependent manner, while induced Zeb1 
expression in epithelial cells had the opposite effect (Figure 78 and 79).  
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Figure 74 Figure 74. Experimental design for FDAome shRNA drop-out screens in epithelial 
(393P) and mesenchymal (344P) murine lung cancer cell lines implanted 
subcutaneously in vivo (nude mice) and grown in parallel in vitro (20 doublings). 
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Table 2. Gene level dropout scores for each of the four screens described in Figure 73. 
For each gene in the custom library, the log10 p-value (logP) of the RSA score is 
displayed, and the rank of the gene within a specific screen. The difference in ranks is 
also displayed for comparison of 393P and 344P. 
  
in-vivo in vitro
gene logP rank logP rank logP rank logP rank rank difference rank difference
Erbb2 -9.5 1 -3.2 11 -3.3 11 -3.5 12 -10 -1
Psmb1 -8.8 2 -13.6 1 -2.8 19 -6.4 2 -17 -1
Raf1 -7.7 3 -7.6 3 0.0 190 -0.5 133 -187 -130
Pik3ca -5.7 4 -2.8 17 -6.9 1 -4.3 7 3 10
Plk1 -5.4 5 -1.1 70 -6.1 3 -6.3 3 2 67
Wee1 -5.0 6 -6.3 5 -1.7 43 -3.0 15 -37 -10
Rac1 -4.3 7 -3.1 15 -2.8 17 -1.8 38 -10 -23
Mapk1 -4.1 8 -2.4 22 -0.7 107 -0.3 157 -99 -135
Cdk6 -3.9 9 -1.3 57 -3.9 8 -4.2 8 1 49
Mtor -3.8 10 -2.0 34 -5.6 4 -1.7 40 6 -6
Prkcd -3.7 11 -3.7 10 -4.5 6 -5.1 4 5 6
Stat3 -3.4 12 -0.8 114 -2.8 21 -2.3 27 -9 87
Bcl2 -3.2 13 -2.3 28 -5.1 5 -1.3 52 8 -24
Pim1 -3.1 14 -0.7 126 -2.1 36 -1.3 56 -22 70
Rrm1 -3.1 15 -4.2 9 -1.1 79 -2.2 29 -64 -20
Myc -3.0 16 -6.9 4 -4.5 7 -4.8 5 9 -1
Xpo1 -3.0 17 -0.7 115 -0.7 113 -1.2 61 -96 54
Met -2.8 18 -0.7 123 -1.6 47 -1.1 70 -29 53
Esr1 -2.8 19 -2.4 24 -2.3 31 -2.8 17 -12 7
Mapk8 -2.8 20 -1.2 62 -1.4 61 -0.9 82 -41 -20
Mapk7 -2.7 21 -0.7 119 -2.8 20 -0.7 105 1 14
Rarg -2.7 22 -2.5 21 -2.2 35 -4.1 10 -13 11
Jak2 -2.7 23 -2.2 29 -0.8 103 -2.6 20 -80 9
Insr -2.7 24 -1.3 58 -1.1 78 -1.1 69 -54 -11
Top2a -2.6 25 -3.1 14 -1.6 46 -1.9 36 -21 -22
Psmd1 -2.6 26 -4.5 7 -3.6 9 -2.0 31 17 -24
Ikbke -2.5 27 -1.8 41 -2.5 25 -0.8 92 2 -51
Egfr -2.4 28 -0.7 117 -1.6 51 -0.8 95 -23 22
Birc5 -2.4 29 -5.9 6 -3.2 15 -2.9 16 14 -10
Blk -2.4 30 -1.1 79 -0.3 155 -0.2 174 -125 -95
Pdgfrb -2.3 31 -0.8 104 -0.7 112 -0.6 118 -81 -14
Src -2.3 32 -1.1 73 -0.7 119 -1.7 41 -87 32
Mcl1 -2.2 33 -0.1 181 -1.3 71 -0.9 80 -38 101
Prkch -2.2 34 -2.0 38 -1.0 87 -0.9 90 -53 -52
Top1 -2.1 35 -3.1 13 -2.3 29 -2.5 22 6 -9
Cdk7 -2.1 36 -0.4 144 -2.4 27 -1.1 64 9 80
Cdk9 -2.1 37 -1.2 68 -1.4 63 -0.9 88 -26 -20
Nfkb1 -1.9 38 -1.4 54 -1.3 67 -0.2 169 -29 -115
Aurkb -1.9 39 -3.2 12 -2.8 18 -2.0 35 21 -23
Dot1l -1.9 40 -0.6 129 -1.9 41 -0.2 180 -1 -51
Chek1 -1.9 41 -3.0 16 -1.5 52 -2.7 18 -11 -2
Prkdc -1.8 42 -1.0 82 -1.5 55 -1.6 44 -13 38
Flt4 -1.8 43 -2.5 20 -3.2 14 -4.1 9 29 11
Parp2 -1.8 44 -0.4 140 -1.1 82 -0.8 96 -38 44
Pgd -1.8 45 -1.9 40 -1.0 85 -1.3 57 -40 -17
Notch1 -1.8 46 -2.4 25 -1.1 81 -0.4 142 -35 -117
Atr -1.7 47 -7.9 2 -1.9 40 -3.8 11 7 -9
Ehmt2 -1.7 48 -1.7 44 -1.2 72 -0.6 127 -24 -83
Lap3 -1.7 49 -0.4 143 -0.4 138 -0.4 151 -89 -8
Esr2 -1.6 50 -1.1 69 -2.4 28 -0.6 123 22 -54
in-vivo in-vitro in-vivo in-vitro
393P vs 344P393P 344P
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Figure 75 Figure 75. Gene rank analysis highlighting the behavior of Raf1 and Mapk1 genes 
in the FDAome in vivo and in vitro screens executed in epithelial (393P) and 
mesenchymal (344P) murine lung cancer cell lines (shRNA dropout score = RSA 
logP). 
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Figure 76 
Figure 76. Heatmap showing significantly upregulated signaling proteins in 
isogenically-matched epithelial and mesenchymal human lung cancer cell lines. Cell 
lines expressed Doxycycline (Dox) inducible miR-200 or Zeb1 where indicated. Zeb1 
was constitutively expressed in HCC827 cells. 
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Figure 77 
Figure 77. Dot plot of p-Erk expression levels from RPPA dataset in a panel of 
mesenchymal and epithelial human and murine lung cancer cells. 
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Figure 78 
Figure 79 
Figure 78. Left: Western blot of the EMT markers Zeb1, E-cadherin, Vimentin and 
MAPK signaling molecules in a panel of human KRAS mutant lung cancer cell lines. 
Western blot of indicated proteins in (Middle) H157 cells after Dox-induced miR-200 
expression for 7 days and (Right) H441 cells after Dox-induced Zeb1 expression at 
indicated time points. 
Figure 79. Left: Time course western blot of indicated proteins in H157 cells with 
Dox induction of miR-200. Right: Western blot of indicated proteins in HCC827 cells 
with stable, constitutive expression of Zeb1. 
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Activation of Mek/Erk signaling in epithelial cells is driven by the Ras-Raf-Mek-
Erk signaling cascade 
Since Mek and Erk are activated by various signaling molecules, we next sought to 
establish the pathway responsible for differential MAPK activation. Analysis of the 
canonical Ras-Raf-Mek-Erk signaling cascade (Figure 80) after reversion of the 
mesenchymal H157 and H1155 KRAS mutant cells to an epithelial state through 
induced, stable, or transient expression of miR-200 showed an increase in Kras binding 
to the Ras binding domain (RBD) of Raf1 (CRaf) followed by activation of MAPK 
signaling (Figure 80 and 81). The observation that MAPK signaling is dependent on 
the EMT status of the cells was noted despite the driver mutation present, as miR-200 
expression activated MAPK signaling in EGFR mutant (HCC827), NRAS mutant 
(H1299), EGFR/RAS wild-type (WT) (H2882), and murine KrasLA1-G12D;p53R172HΔG/+ 
(KP) lung cancer cells (Figure 82 and 83). Moreover, miR-200 expression upregulated 
MAPK signaling in epithelial, non-transformed BEAS2B cells with constitutive 
expression of mutant KRASG12D or EGFRΔ722–726 (59) (Figure 84), demonstrating that 
this process is independent of oncogenic and co-mutational events. 
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Figure 80 
Figure 80. Left: Schematic of Ras-Raf-Mek-Erk MAPK pathway. Top Right: Western 
blot of Kras from Ras-GTP pulldown with the Ras binding domain (RBD) of Raf1 
following miR-200 induction in mesenchymal H157 lung cancer cell line. Bottom 
Right: Western blots of whole cell lysates of MAPK signaling molecules in H157 cells 
with induced miR-200 expression. 
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Figure 81 
Figure 82 Figure 82. Western blots of MAPK signaling proteins in HCC827 (EGFR mutant), 
H1299 (NRAS mutant), and H2882 (EGFR and NRAS WT) human lung cancer cell 
lines after transient expression of miR-200a/b/c. 
Figure 81. Left: Western blot of Kras after Ras-GTP pulldown with Raf1-RBD as 
well as total Kras levels in whole cell lysates of H157 cells with stable miR-200 
expression. Middle: Western blot of MAPK signaling proteins in H157 cell lysates 
after with miR-200 expression. Right: Western blot of Kras after Ras-GTP pulldown 
with Raf1-RBD in mesenchymal H1155 cells with transient miR-200 expression. 
Total cell lysates were immunoblotted for MAPK signaling proteins. 
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Figure 83 
Figure 84 Figure 84. Western blots of MAPK signaling proteins in non-transformed BEAS2B 
epithelial human lung cell line expressing mutant KRAS or mutant EGFR in 
conjunction with transient expression of miR-200a/b/c. 
Figure 83. Western blot MAPK signaling proteins in mesenchymal 344SQ murine 
lung cancer cell line with (Left) transient or (Right) Dox inducible miR-200 
expression. 
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To verify that the Ras-Raf-Mek pathway is necessary to activate p-Erk, we transiently 
knocked down KRAS by shRNA after miR-200 induction and observed a significant 
reduction in MAPK signaling in both epithelial and mesenchymal cells (Figure 85). 
Interestingly, KRAS knockdown caused activation of cleaved caspase-3, indicating that 
Kras is still necessary for cell survival despite the EMT status and suppression of 
MAPK signaling. Similarly, chemical inhibition of pan-Raf enzymatic activity and siRNA 
knockdown of Raf isoforms individually or in combination demonstrated that MAPK 
activation was predominantly dependent on the enzymatic function of the CRaf isoform 
(Figure 86 and 87). Knockdown of all three Raf isoforms most significantly reduced p-
Mek/p-Erk in miR-200 expressing cells, but not in mesenchymal control cells, 
suggesting that miR-200 potentially aids Raf heterodimerization and activation by Kras 
to drive MAPK signaling (Figure 87).  
 In addition to the Ras-Raf pathway, we also examined the alternative Fak-Rac-
Pak signaling pathway for p-Mek/p-Erk activation (Figure 88). Stable or induced miR-
200 expression in H157 cells decreased p-Fak levels, consistent with our previous work 
(58), but increased levels of p-Pak2 (Figure 88 and 89). Small molecule inhibition of 
Fak had no effect on MAPK signaling, while siRNA mediated knockdown of PAK1 
and/or PAK2 showed only partial contribution of Pak2 in activating MAPK signaling, but 
to a much lower degree than Ras-Raf (Figure 89 and 90). 
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Figure 85 Figure 85. Western blots of MAPK signaling proteins in H157 cells with induced 
miR-200 expression after KRAS knockdown by shRNA. 
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Figure 86 
Figure 86. Western blots of MAPK signaling proteins in H157 cells with induced 
miR-200 expression after inhibition of pan-Raf enzymatic activity for 24 hours with 
TAK-632. 
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Figure 87 Figure 87. Western blots of MAPK signaling proteins in H157 cells with induced 
miR-200 expression after 48hr siRNA-mediated knockdown of Raf isoforms 
individually or in combination. 
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Figure 88. Left: Schematic of Fak-Rac-Pak-Mek-Erk signaling pathway. Middle: 
Western blot of activated p-Fak and p-Pak in H157 cells with stable miR-200 
expression. Right: Time course western blot of activated p-Pak in H157 cells with 
Dox inducible miR-200 expression. 
Figure 88 
Figure 89 Figure 89. Western blot of indicated proteins after chemical inhibition of Fak 
enzymatic activity in H157 cells with 7-day Dox induced miR-200 expression. 
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Figure 90 Figure 90. Western blot of indicated proteins after individual or combinatorial siRNA-
mediated knockdown of Pak1 and Pak2 in H157 cells with 7-day Dox induced miR-
200 expression. 
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Regulation of MAPK pathway signaling is linked to the EMT state by differential 
expression of the scaffold protein Il17rd 
We next sought to ascertain the mechanism of MAPK activation in epithelial cells 
expressing miR-200. To determine if signaling was due to upstream growth factor 
stimulation of receptor tyrosine kinases or other mitogen activated receptors, the KRAS 
mutant H157 cells in the presence or absence of miR-200 expression were cultured in 
serum-free media for 24 hrs and stimulated with either media containing fetal bovine 
serum (FBS), continued serum-free conditions, or epithelial growth factor (EGF) for 4 
hrs. In mesenchymal cells, there was a significant reduction in MAPK signaling under 
serum-free conditions compared to FBS stimulation, while EGF only marginally 
activated signaling (Figure 91). However, cells with miR-200 induction continued to 
have increased MAPK signaling regardless of culture conditions (Figure 91), which 
suggests that miR-200-dependent activation of the MAPK pathway in KRAS mutant 
cells occurs through an intracellular component independent of extrinsic factors. 
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Figure 91 Figure 91. Western blot of MAPK signaling molecules in H157 cells +/- miR-200 expression after 24hr serum-free starvation, followed by stimulation with complete 
serum media, serum-free media, or EGF for 4 hours. 
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Since miR-200-mediated activation of Mek/Erk signaling occurs predominantly through 
the Ras-Raf signaling junction, is dependent on multiple Raf isoforms, and is 
intracellularly regulated, our data implied that MAPK regulation by EMT was dependent 
on changes in inhibitory or scaffolding proteins. We performed qPCR analysis for 
expression of MAPK inhibitory and scaffold genes reported to interact with Raf (15), 
with and without miR-200 induction (Figure 92 and 93). Inhibitory genes with at least 
50% decrease or scaffold genes with at least 2-fold increase in expression after miR-
200 induction were selected for further analysis (Figure 92). Increased expression of 
SPRY4 and the various DUSP genes (Figure 93) after miR-200 induction is consistent 
with feedback inhibition responses due to upstream activation of the MAPK pathway 
(16-18, 21, 22). As SPRY1 was the only inhibitory gene significantly downregulated by 
over 50% with miR-200 expression, we proceeded to knockdown SPRY1 by siRNA in 
H157 cells or transiently express SPRY1 in miR-200 expressing H157 cells and 
observed no significant effect on MAPK signaling in either case (Figure 94). QPCR 
analysis of various Raf-associated scaffolding genes (Figure 92 and 93) identified 
KSR2, SFN (14-3-3σ), CNK2, SHOC2, and Il17RD as potential targets that were 
significantly upregulated at least 2-fold with miR-200 expression (Figure 92). Western 
blot validation of the qPCR data showed no significant differences in SHOC2 or CNK2 
protein levels (Figure 95). Although miR-200 expression significantly increased 14-3-
3σ protein and KSR2 mRNA levels, respectively, knockdown of either gene after miR-
200 induction had no effect on MAPK signaling (Figure 96). 
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Figure 92 Figure 92. QPCR analysis for relative expression of SPRY1, KSR2, 14-3-3σ/SFN, 
CNK2, SHOC2, and IL17RD in H157 cells with inducible miR-200 expression. 
Asterisks (*) represent significance value of p<0.01. 
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Figure 93 
Figure 94 
Figure 94. Left: Western blot of Spry1 and MAPK signaling molecules after 96hr 
siRNA knockdown of SPRY1 in mesenchymal H157 cells. Right: Western blot of 
Spry1 and MAPK signaling molecules in H157 cells with inducible miR-200 after 
96hr SPRY1 transient overexpression. 
Figure 93. QPCR analysis of (Left) MAPK inhibitory genes, (Middle) DUSP gene 
family, and (Right) MAPK scaffold genes in H157 cells with inducible miR-200 
expression. 
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Figure 95 
Figure 95. Western blot of Shoc2 and Cnk2 in H157 cells with inducible miR-200 
expression. 
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Figure 96 Figure 96. Left: Western blot of indicated proteins after 96hr siRNA knockdown of 
14-3-3σ in H157 cells with inducible miR-200 expression. Middle: Western blot of 
MAPK signaling molecules after 96hr siRNA knockdown of KSR2 in H157 cells with 
inducible miR-200 expression. Right: qPCR analysis of KSR2 mRNA levels after 
96hr siRNA knockdown of KSR2. 
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We next focused our analysis on the regulatory role of Il17rd on MAPK signaling. 
Correlation analysis of IL17RD mRNA expression to our previously reported 76-gene 
EMT signature score (40) in a panel of 77 human lung cancer cell lines showed a 
statistically significant, strong inverse correlation between IL17RD and EMT (Figure 
97). Validation of the correlation analysis and IL17RD qPCR by Western blotting in a 
panel of epithelial and mesenchymal Ras mutant human lung cancer cell lines 
confirmed higher basal Il17rd expression in epithelial cells (Figure 98). Additionally, 
Il17rd levels were induced in mesenchymal H157 cells upon miR-200 expression and 
suppressed by Zeb1 expression in epithelial H441 cells (Figure 98). Knockdown of 
IL17RD by shRNA in miR-200 expressing H157 cells significantly reduced MAPK 
signaling (Figure 99), while overexpression of IL17RD in mesenchymal H157 and 
A549 cells increased MAPK signaling (Figure 99). Although IL17RD was initially 
implicated in inhibiting fibroblast growth factor (FGF)-induced MAPK signaling (115), in 
FGF-independent contexts, IL17RD has been shown to promote MAPK signaling (116, 
117). Consistent with these reports, analysis of Fgfr1 protein levels revealed a 
reciprocal expression to Il17rd, in which mesenchymal cells have greater expression of 
Fgfr1 compared to epithelial cells (Figure 100), and transient IL17RD overexpression 
led to a decrease in Fgfr1 protein levels (Figure 100). 
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Figure 97 Figure 97. Correlation plot of IL17RD gene expression and EMT scores of 77 
human lung cancer cell lines. 
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Figure 98 
Figure 98. Western blots of Il17rd in (Top) a panel of human epithelial and 
mesenchymal KRAS mutant lung cancer cell lines and (Bottom) H157 or H441 cells 
with induced miR-200 or Zeb1 expression, respectively. 
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Figure 99 
Figure 99. Left: Western blot of Il17rd and MAPK signaling molecules after transient 
shRNA knockdown of IL17RD in H157 cells with induced miR-200 expression. 
Middle and Right: Western blot of Il17rd and MAPK signaling molecules after 48hr 
constitutive expression of IL17RD in (Middle) H157 and (Right) A549 cells. 
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Figure 100 
Figure 100. Left: Western blot of Fgfr1 in a panel of epithelial and mesenchymal 
Ras mutant human lung cancer cell lines (top), in mesenchymal H157 cells after Dox 
inducible miR-200 expression (middle), and in epithelial H441 cells after Dox 
inducible Zeb1 expression (bottom). Top Right: Western blot of Fgfr1 in H157 cells 
with inducible miR-200 or vector control after transient shRNA knockdown of 
IL17RD. Bottom Right: Western blot of Fgfr1 in H157 and A549 cells after 48hr 
transient overexpression of IL17RD. 
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Due to the strong correlation of IL17RD to EMT, we next sought to understand the 
regulatory mechanism of Zeb1 or miR-200 on IL17RD gene expression. Analysis of the 
human IL17RD promoter region using the JASPAR transcription factor database 
(http://jaspar.genereg.net/) predicted multiple potential Zeb1 E-box recognition sites 
(Figure 101) responsible for transcriptional repression of gene expression (45, 48, 57, 
118). Zeb1 chromatin immunoprecipitation (ChIP) qPCR assays of the endogenous 
IL17RD promoter in mesenchymal H157 cells with or without miR-200 expression 
confirmed direct binding of Zeb1 to the IL17RD promoter with the strongest signal 
occurring 195 and 680 base pairs upstream of IL17RD transcriptional start site (Figure 
101). Luciferase reporter assays with the wild-type IL17RD promoter region confirmed 
transcriptional repression by ZEB1, which was abrogated by introduction of mutations 
into the two main ZEB1 binding sites (as assessed by ChIP) individually and in 
combination (Figure 101). 
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Figure 101 Figure 101. Left: Schematic of human IL17RD promoter region containing predicted 
Zeb1 binding sites represented by color-coded ellipses. Black arrows indicate 
location of qPCR primers used to amplify genomic region containing potential Zeb1 
binding sites in IL17RD promoter after Zeb1 chromatin immunoprecipitation (ChIP). 
The IL17RD promoter was cloned 1,066 base pairs upstream of the transcriptional 
start site and inserted into a luciferase reporter vector. Mutations of potential Zeb1 
binding sites indicated with yellow X. Middle: Fold enrichment by qPCR analysis of 
IL17RD promoter segments containing potential Zeb1 binding sites after 
endogenous Zeb1 ChIP in H157 cells with inducible vector control or miR-200 
expression, using Zeb1 antibody or mock IgG control antibody. Primers used for 
qPCR amplification labeled in graph legend corresponding to numbers on black 
arrows (left). Right: Relative luciferase activity of IL17RD promoter reporter 
constructs (left) transfected into epithelial H441 cells with induced GFP control or 
Zeb1 expression. Relative luciferin signal was normalized to promoter-less vector 
control signal. 
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Mesenchymal lung cancer cells and tumors are resistant to MEK inhibition 
The increase in MAPK levels in epithelial cells concomitant with the decrease in various 
other signaling pathways involved in drug resistance and invasion/metastasis such as 
p-Fak, p110α, p-Stat3, p-PKCα, and Axl (40, 58, 89, 100, 119-123) (Table 2 and 
Figure 89), suggested that epithelial lung cancer cells were more dependent on MAPK 
signaling for growth and survival. Treatment of a panel of human and murine KRAS 
mutant lung cancer cell lines, stratified as either epithelial or mesenchymal based on 
previous profiling (33, 48, 56) (Figure 78), confirmed that epithelial cells were more 
sensitive to the MEK inhibitor Selumetinib (AZD6244) (Figure 102). Furthermore, 
resistant cell lines were re-sensitized to MEK inhibition upon miR-200 induction (Figure 
102) while epithelial cells became more resistant to MEK inhibition with Zeb1 
expression (Figure 102). Interestingly, constitutive expression of Il17rd in 
mesenchymal H157 and 344SQ cells reactivated MAPK signaling and sensitized the 
resistant lines to MEK inhibitor treatment (Figure 102). 
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Figure 102 
Figure 102. Growth inhibition response after 72hr AZD6244 MEK inhibitor treatment 
in: 
Top left: A panel of epithelial and mesenchymal human lung cancer cell lines with 
Ras mutations. Top Middle: Mesenchymal H157 cells with inducible miR-200 
expression. Top Right: Epithelial H441 cells with inducible Zeb1 expression. Center 
Left: A panel of epithelial and mesenchymal murine KP lung cancer cell lines. Center 
Middle: Mesenchymal murine 344SQ cells with inducible miR-200 expression. 
Center Right: Epithelial murine 393P cells with inducible Zeb1 expression. Bottom 
Left: Mesenchymal H157 cells with stable Il17rd expression. Bottom Middle: 
Mesenchymal murine 344SQ cells with stable Il17rd expression. 
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To validate our in vitro findings in an in vivo context, we first analyzed primary 
syngeneic tumors generated by subcutaneous implantation of epithelial 393P and 
mesenchymal 344SQ murine lung cancer cells in syngeneic WT mice (33). 
Immunohistochemical (IHC) staining of the tumor tissues for Il17rd, p-Erk, and EMT 
markers (high nuclear Zeb1, low/mislocalized E-cadherin, and high vimentin) showed a 
strong, positive correlation between Il17rd and p-Erk with an inverse correlation of the 
two markers to EMT (Figure 103). Consistent with these findings, in vivo administration 
of AZD6244 significantly reduced tumor growth only in epithelial 393P tumors, while 
mesenchymal 344SQ tumors were highly resistant to treatment. However, despite the 
pronounced efficacy, 80% of 393P tumors eventually developed resistance to MEK 
inhibition, reaching comparable sizes to control tumors by 12 weeks, and formed 
metastatic lung lesions, which are not usually observed in this model (Figure 104). IHC 
analysis of the vehicle control (393P Solvent) and AZD6244-sensitive (393P AZD6244) 
after 7 weeks, and the AZD6244-resistant (393P AZD-R) primary 393P tumors after 12 
weeks confirmed the efficacy of AZD6244 in suppressing p-Erk levels and revealed that 
the resistant tumors had undergone EMT as assessed by high Zeb1, low E-cadherin, 
and high vimentin levels compared to control tissues (Figure 105). Interestingly, 
vimentin levels began to increase even in AZD6244-sensitive 393P tumors following 
MEK inhibition. To determine if in vivo sensitivity to MEK inhibition was a result of high 
miR-200 levels, we induced miR-200 expression in resistant 344SQ cells and treated 
syngeneic tumors with AZD6244. Although miR-200 expression alone significantly 
decreased tumor growth, combination with AZD6244 had an additive effect that 
reduced average tumor size by over 90% (Figure 106), similar to the response of 
epithelial 393P tumors with high basal levels of miR-200 expression. 
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Figure 103 
Figure 104 Figure 103. H&E, Il17rd, p-Erk, Zeb1, E-cadherin, and Vimentin IHC stains of 
primary syngeneic tumor tissues generated by subcutaneous injection of epithelial 
393P and mesenchymal 344SQ murine lung cancer cell lines in syngeneic wild-type 
mice (n=8 tumors per group). Bright-field microscopy at 20x magnification. Scale 
bars, 100 µm. 
Figure 104. Left: Tumor volume measurements at indicated time points of 393P and 
344SQ subcutaneous tumors in syngeneic wild-type mice after daily treatment with 
25 mg/kg AZD6244 MEK inhibitor or solvent vehicle control. Treatment start time 
and endpoint for control mice group are denoted with red arrows. Purple data points 
represent 393P tumors initially responsive to MEK inhibition that developed 
resistance over time. Middle: Tumor volume measurements at Week 7 (4 weeks of 
AZD6244 treatment, endpoint). Right: Quantification of lung metastatic surface 
nodules of indicated experimental groups at Week 7 of experiment. Circled purple 
data points represent lung metastatic surface nodules at Week 12 in 393P tumors 
that developed resistance to AZD6244 (393P AZD-R). 
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Figure 105. Stains for indicated markers of 393P tumors in mice that received 
solvent or AZD6244 until Week 7 of experiment in (Figure 103) (top and middle 
panels). Staining of 393P tumors that developed resistance to AZD6244 (393P AZD-
R) at Week 12 of experiment in (Figure 103) (bottom panel). Bright- field microscopy 
at 20x magnification. Scale bars, 50 µm. (n=5 tissues per group). 
Figure 105 
Figure 106 Figure 106. Left: Tumor volume measurements at indicated time points of 344SQ 
cells +/- inducible miR-200 expression injected subcutaneously into syngeneic wild-
type mice and treated with 25 mg/kg AZD6244 or vehicle control. Starting time of 
treatment denoted by red arrow. Middle: Final tumor volume measurements at Week 
9 (5 weeks of treatment) of experiment. Right: Quantification of lung metastatic 
surface nodules of indicated experimental groups at Week 9 of experiment. 
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Mesenchymal de-differentiation of lung tumors in Kras mutant mouse models is 
sufficient to suppress MAPK signaling and confer resistance to MEK inhibition 
Murine co-clinical trials with the MEK inhibitor AZD6244 in combination with docetaxel 
have shown that the co–mutational status of tumors, such as loss of p53, contributed to 
therapy resistance (27). Previous studies by our group have reported that 
heterogeneous Kras;p53 mutant lung tumors display regions of poorly differentiated 
tumors, as assessed by changes in expression of EMT markers, compared to mutant 
KrasG12D tumors (56). These findings suggest that poorly differentiated Kras;p53 mutant 
lung tumors have undergone EMT, producing drug resistance. Thus, we next analyzed 
lung tissues with autochthonous tumors from conditional KrasLSL-G12D (KrasG12D) and 
KrasLSL-G12D;p53fl/+ (KP-/+) mice, generated through intratracheal administration of 
adenovirus expressing Cre recombinase (124). Histological analyses demonstrated 
that KP-/+ mice (4 – 6 months post-induction) displayed more numerous and larger 
tumors than KrasG12D mice, with greater inter- and intratumoral heterogeneity, 
presenting a mixture of well- and poorly-differentiated tumors based on analysis of EMT 
markers (Figure 107 and Figure 110). Similar to our observations in syngeneic 
primary tumors (Figure 103), poorly-differentiated tumors exhibiting mesenchymal 
marker patterns had low levels of Il17rd and p-Erk, while well-differentiated, epithelial 
tumors had high levels of Il17rd and p-Erk (Figure 107). 
 To assess whether our findings in the KP mice were due to EMT driven by 
diminished miR-200 expression and not a secondary effect of p53 loss, we utilized 
mice with loxP sites flanking the miR-141/200c stem-loop in the miR-141/200c locus 
(95, 96) and crossed them with the KrasLSL-G12D mice. Intratracheal delivery of 
adenoviral Cre recombinase produced mice with an activated KrasG12D and loss of miR-
144 
 
141/200c (KM). Mice expressing the targeted alleles were validated by PCR 
amplification of the stem-loop loxP site (Figure 108). Additionally, the targeting vector 
inserts a promoter-less lacZ gene driven by the endogenous miR-141/200c promoter 
activity after Cre-mediated removal, further validating successful locus targeting in both 
KM tumor tissues and in the airway epithelium of miR-141/200c-/+ (M) mice (Figure 
108). Verification of miR-141/200c knockout by qPCR analysis of KM lung tumor 
tissues showed significant reduction in miR-141/200c levels compared to KrasG12D 
tumors with no compensatory effect by other miR-200 family members (Figure 109). 
Monthly analysis of murine lung tissues at 1 to 6 months post-induction revealed 
greater lung tumor numbers as well as overall tumor area in KM mice compared to 
KrasG12D mice as measured by micro-CT scans and H&E-stained tissues. However, 
overall tumor area in KM mice were smaller than KP-/+ tumors (Figure 110 and 111). 
No tumor growth was observed in mice harboring only the miR-141/200c-/+ mutation 
without an activated KRAS allele within the 6 month time course (Figure 110). Analysis 
by IHC of KM tumor tissues for EMT markers showed higher numbers of poorly-
differentiated tumor regions that correlated with low levels of Il17rd and p-Erk relative to 
KrasG12D tumors (Figure 107 and Figure 110). Interestingly, we also observed tumor 
heterogeneity in KM mice similar to that of the KP-/+ mice, with certain regions 
possessing well differentiated, epithelial tumors with high Il17rd and p-Erk levels.  
 We next sought to assess the sensitivity of the different KRAS mutant murine 
lung cancer models to MEK inhibition. Three months post-induction of lung tumors in K, 
KP and KM animals by adeno-Cre, tumor formation was confirmed by micro-CT scans 
and daily doses of single-agent AZD6244 were administered to mice. Micro-CT image 
analysis of changes in overall lung tumor area demonstrated that the predominantly 
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epithelial lung tumors from mice with the single KrasG12D mutation were sensitive to 
MEK inhibition, while KP-/+ and KM lung tumors were more resistant after 4 weeks of 
treatment (Figure 112). Taken overall, these data demonstrate that EMT is sufficient to 
regulate IL17rd levels and MAPK signaling in autochthonous KRAS mutant lung 
cancers, thereby mediating resistance to MEK inhibitors. 
 
  
Figure 107 Figure 107. H&E, Il17rd, p-Erk, Zeb1, E-cadherin, and Vimentin IHC stains of 
different lung tumor tissue regions as denoted by zoomed-in sections of KrasG12D, 
KP-/+, and KM mice (n=6 tissues per group). Bright-field microscopy at 20x 
magnification. Scale bars, 100 µm. 
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Figure 108 Figure 108. Top: Agarose gel image of PCR product genotyping the murine miR-
141/200c locus flanked by loxP sites (fl). Higher band indicates floxed locus that will 
be deleted upon adeno-Cre induction (mut) while lower band is wild-type (WT) locus. 
Bottom: Lung airway epithelium of miR-200-/+ mice and lung tumor tissues of KM 
mice stained with β-gal. Scale bars, 200µm. 
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Figure 109 
Figure 109. QPCR analysis of miR-200 family expression in lung tumors from 
KrasG12D, KP-/+, and KM mice. 
Figure 110 
Figure 110. Left: H&E stains of lung tissue sections from various KrasG12D, KP-/+, 
and KM mice. Right: Additional H&E, Zeb1, p-Mek, and p-Erk IHC stains of different 
lung tumor tissue regions as denoted by black zoom box in KrasG12D, KP-/+, and KM 
mice (n=6 tissues per group). Bright field microscopy at 20x magnification. Scale 
bars, 200µm. 
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Figure 111 Figure 111. Average lung tumor areas of KrasG12D, KP-/+, and KM mice as assessed 
by micro-CT imaging of mice lungs over a course of 6 months post-induction with 
adeno-Cre.  Mice with miR-200c/141-/+ (M) only showed no tumor formation. 
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Figure 112 Figure 112. Top Left: Percent change in overall lung tumor area of age-matched 
KrasG12D, KP-/+, and KM mice after 4 weeks of daily treatment with 25 mg/kg 
AZD6244, as assessed by micro-CT imaging of mice lungs. Bottom Left: Trendline 
of percent change in overall tumor area at indicated time points of KrasG12D, KP-/+, 
and KM mice over 4 weeks of daily treatment with AZD6244. Right: Representative 
cross-sectional micro-CT images of KrasG12D, KP-/+, and KM mice lungs prior to 
AZD6244 administration (Week 0) and at the treatment endpoint (Week 4). Yellow 
circles outline representative target lesions. 
 
150 
 
Mocetinostat reverts EMT, derepresses IL17rd expression, and sensitizes 
resistant cancer cells to MEK inhibition 
Identifying combinatorial treatment strategies with MEK inhibitors to reduce tumor 
growth and progression is vital for improving patient survival. Previous studies have 
shown that the class I histone deacetylase (HDAC) inhibitor mocetinostat reverts the 
EMT phenotype through restoration of epithelial microRNAs, including the miR-200 
family (50). Treatment of mesenchymal H157 cells with mocetinostat induced miR-200 
expression and reversed EMT at the molecular level resulting in increased Il17rd 
expression, increased MAPK signaling, and decreased FGFR1 levels (Figure 113 and 
114). To verify that the observed changes were independent of secondary effects due 
to histone acetylation, H157 cells were treated with the pan-HDAC inhibitor Trichostatin 
A (TSA) and showed no significant changes in either EMT markers or MAPK signaling 
molecules (Figure 115). Mocetinostat treatment of 344SQ syngeneic tumors produced 
an increase in Il17rd and p-Erk levels by IHC analysis, concomitant with an increase in 
cell-cell adherence junctions as characterized by increased E-cadherin localization to 
the cell membrane (Figure 116). Although we did not observe a significant change in 
Zeb1 or vimentin levels by IHC after mocetinostat treatment (Figure 117), qPCR 
analysis of the mocetinostat-treated 344SQ tumors showed a significant upregulation of 
both miR-200c and IL17RD, along with a significant decrease in N-cadherin, 
demonstrating functional suppression of Zeb1 (Figure 117 and 118). As previously 
reported, these findings suggest that in addition to direct promoter binding, Zeb1 can 
functionally repress expression of epithelial-associated genes through recruitment of 
histone deacetylases (50, 51, 125-127). 
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Since epithelial cancer cells are sensitive to MEK inhibition, reversion of EMT in 
mesenchymal human and murine lung cancer cells in vitro with mocetinostat increased 
sensitivity to AZD6244 treatment (Figure 119). In vivo combinatorial administration of 
mocetinostat and selumetinib in mice bearing syngeneic 344SQ mesenchymal tumors 
had an additive effect on reducing average tumor size compared to single agent 
AZD6244 treatment (Figure 120). Mocetinostat alone significantly reduced tumor 
growth rate, with no observed decrease in the number and size of lung metastatic 
nodules. However, lung metastatic nodules were drastically reduced in both number 
and size with dual HDAC and MEK inhibition (Figure 120). To simulate the genetic 
alterations and tumor heterogeneity observed in lung adenocarcinoma patients, we 
treated the spontaneous KrasLA1-G12D;p53R172HΔG/+ (KP) mice between 7 to 8 months of 
age with AZD6244 alone or in combination with mocetinostat. Comparable with the 
adeno-Cre conditional lung tumor mouse models, KrasLA1-G12D (Kras) tumors were 
sensitive to MEK inhibition while KP tumors were resistant (Figure 121). However, 
micro-CT image analysis demonstrated that combinatorial treatments of KP mice with 
mocetinostat and AZD6244 significantly reduced overall tumor area (Figure 121).  
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Figure 113 
Figure 114 Figure 114. Western blots of Fgfr1 in H157 cells after time course treatment with 
mocetinostat. 
 
Figure 113. Left: QPCR analysis for relative expression of miR-200a, miR-200b, 
and miR-200c in H157 cells after 72 hr treatment with mocetinostat. Asterisks (*) 
indicate significance value of p<0.01. Middle: Western blots of EMT markers in H157 
cells after time course treatment with mocetinostat. Right: Western blots of Il17rd 
and MAPK signaling proteins in H157 cells after time course treatment with 
mocetinostat. Acetylated histone (H3K9) is included to confirm HDAC inhibition by 
mocetinostat. 
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Figure 115 
Figure 115. Western blot of indicated proteins in H157 cells treated with trichostatin 
A (TSA) for indicated time course. Acetyl histone H2B lysine residue 5 used as 
verification for HDAC inhibition. 
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Figure 116 
Figure 117 
Figure 116. H&E, Il17rd, p-Erk, and E-cadherin IHC stains of primary 344SQ tumor 
tissues in syngeneic wild-type mice after 3 week treatment with 80 mg/kg 
mocetinostat or solvent control daily (n=5 tumors per group). Bright-field microscopy 
at 20x magnification. Scale bars, 100 µm. 
 
Figure 117. Left: Zeb1 and vimentin IHC stains of primary 344SQ tumor tissues in 
syngeneic wild-type mice after 3 week treatment with 80 mg/kg mocetinostat or 
solvent control daily (n=5 tumors per group). Bright-field microscopy at 20x 
magnification. Scale bars, 100 µm. Right: QPCR analysis of Zeb1, N-cadherin, and 
Vimentin expression in 344SQ tumor tissues treated with mocetinostat or solvent 
control from samples above. Technical triplicates of 5 tumor tissue samples from 
each treatment group were analyzed for each qPCR. 
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Figure 118 Figure 118. QPCR analysis of miR-200c and Il17RD expression in 344SQ tumor 
tissues treated with mocetinostat or solvent control from Figure 115. Technical 
triplicates of 5 tumor tissue samples from each treatment group were analyzed for 
each qPCR. 
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Figure 119 
Figure 119. Growth inhibition response of mesenchymal H157, A549, 344SQ, and 
344P human and murine lung cancer cell lines after 72hr treatment with single agent 
AZD6244 or in combination with mocetinostat. 
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Figure 120 
Figure 120. Left: Tumor volume measurements at indicated time points of 344SQ 
subcutaneous syngeneic tumors treated daily with single agent 25 mg/kg AZD6244, 
single agent 80 mg/kg mocetinostat, or both drugs in combination. Starting time of 
treatment denoted by red arrow. Middle: Final tumor volume measurements at Week 
6 (3 weeks of treatment) of experiment. Right: Quantification of lung metastatic 
surface nodules of indicated treatment groups at Week 6 of experiment. 
 
Figure 121 
Figure 121. Top Left: Percent change in overall tumor area of KrasLA1-G12D (Kras) 
and KrasLA1-G12D;p53R172HΔG/+ (KP) mice after 4 weeks of daily treatment with single 
agent 25 mg/kg AZD6244 or 5 weeks of daily combinatorial treatment with AZD6244 
and 80 mg/kg mocetinostat in KP mice. Bottom Left: Trendline of percent change in 
overall tumor area at indicated time points of Kras and KP mice with single agent 
AZD6244 treatment or combinatorial treatment with AZD6244 and mocetinostat. 
Right: Representative micro-CT images of KrasG12D and KP mice prior to treatment 
(Week 0) and at treatment endpoint. 
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Patients with poorly differentiated lung adenocarcinomas display lower levels of 
phosphorylated Erk, inversely correlating with Zeb1 expression 
Finally, we wanted to determine the correlation between p-Erk, Il17rd, and EMT in 
human lung cancer patient samples to evaluate the clinical relevance of our findings. 
Pathological assessment of cytoplasmic and nuclear p-Erk H-scores by IHC staining in 
a cohort of patient lung tumor tissues (n = 451) showed significantly higher expression 
of p-Erk in patients with lung adenocarcinomas (ADC) versus patients with squamous 
cell carcinoma (SCC) (Figure 122 and 123). Pathological analyses also revealed that 
poorly differentiated ADC tumors have significantly lower levels of nuclear p-Erk when 
compared to moderately differentiated ADC tumors (Figure 124). We were unable to 
compare p-Erk expression to differentiation grade in SCC patients due to the lack of 
well differentiated tumors as well as a low sample number of moderate grade tissues 
(data not shown). Although cytoplasmic p-Erk levels showed a decreasing trend in 
poorly differentiated tumors, these changes were not statistically significant (Figure 
124). 
 Since previous studies have demonstrated that Zeb1 is a major driver of EMT in 
lung adenocarcinomas, we next wanted to determine the correlation between Zeb1 and 
p-Erk expression in patient lung tumors. Utilizing data from Zeb1 IHC stains performed 
in a previous study (56) on the same patient tissue cohorts here, we compared H-score 
values of Zeb1 and p-Erk in each patient tumor sample and observed a moderate but 
significant negative correlation between Zeb1 and nuclear/cytoplasmic p-Erk in ADC 
histologic subtypes but not SCC samples (Figure 125 and 126). Due to the lack of 
optimized Il17rd antibodies that produced IHC stains of clinically acceptable quality for 
scoring, we analyzed gene expression profiles in patient lung tumor samples from the 
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PROSPECT dataset and observed a significant inverse correlation between IL17RD 
and ZEB1 mRNA levels (Figure 127). IL17RD expression is not prognostic of overall 
patient survival (Figure 127), suggesting that high Il17rd levels do not confer tumor 
growth reduction but are only predictive of sensitivity or response to MEK inhibitors, 
which none of the patients received. Collectively, our data demonstrate a model by 
which a Zeb1-driven EMT in mesenchymal lung cancers directly suppresses Mek/Erk 
signaling through transcriptional repression of IL17RD, resulting in upregulation of 
alternative signaling pathways that promote MEK inhibitor resistance and 
invasion/metastasis. Induction of miR-200 suppresses Zeb1 function and increases 
MAPK signaling/dependency, thereby sensitizing KRAS mutant lung cancers to MEK 
inhibition (Figure 128). 
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Figure 122 
Figure 123 
Figure 122. Examples of well- and poorly-differentiated human lung ADC tissue 
sections stained by IHC for Zeb1 and p-Erk. Scale bars, 200 µm. 
 
 
Figure 123. Left: Average final nuclear H-score of p-Erk in tumor cells of ADC or 
SCC specimens. Right: Average final cytoplasmic H-score of p-Erk in tumor cells of 
ADC or SCC specimens. 
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Figure 124 
Figure 125 
Figure 124. Left: Average final nuclear H-score of p-Erk in ADC specimens of 
different differentiation grades. Right: Average final cytoplasmic H-score of p-Erk in 
ADC specimens of different grades. 
 
 
Figure 125. Cluster plot analysis of Spearman’s rank correlation between Zeb1 and 
nuclear p-Erk H-score in ADC specimens. 
 
 
162 
 
 
  
Figure 126 
Figure 127 
Figure 126. Left: Cluster plot analysis of Spearman’s rank correlation between Zeb1 
and cytoplasmic p-Erk H-score in ADC specimens. Middle and Right: Cluster plot 
analysis of Spearman’s rank correlation between Zeb1 and (Middle) cytoplasmic and 
(Right) nuclear p-Erk H-score in SCC specimens. 
 
 
Figure 127. Left: Cluster plot analysis of Spearman’s rank correlation between 
ZEB1 and IL17RD mRNA levels in human lung cancer patient tumor samples from 
PROSPECT dataset. Right: Kaplan–Meier survival analysis by log-rank significance 
test of IL17RD mRNA expression levels versus overall lung cancer patient survival 
from PROSPECT dataset. 
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Figure 128 Figure 128. Proposed model demonstrating differential MAPK signaling pathway 
activation and sensitivity to MEK inhibitor treatment between epithelial and 
mesenchymal lung cancer cells due to Zeb1 regulation of Il17rd expression. 
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CHAPTER 4: DISCUSSION 
 
Project 1: ZEB1 Induces LOXL2-Mediated Collagen Stabilization and Deposition 
in the Extracellular Matrix to Drive Lung Cancer Invasion and Metastasis 
 
The high mortality rate of lung cancer, especially histologic subtypes with KRAS 
mutations, is attributed to the rapid development of therapy resistance and the 
propensity of the disease to metastasize to vital organs. Exacerbating matters, patients 
who receive first-line chemotherapies or targeted drug treatments often relapse and 
acquire distant metastatic lesions. Thus, we sought to investigate the underlying 
biological functions responsible for drug resistance and metastasis to identify potential 
biomarkers and therapeutic targets to improve overall patient survival. Utilizing the KP 
mouse model which possesses the two most commonly mutated genes in lung 
adenocarcinoma, initial work by our group revealed that Zeb1 suppression of miR-200 
and induction EMT is crucial for lung cancer invasion and metastasis (32, 33, 48, 53, 
55, 56, 58, 59, 89, 91, 128). Additionally, our finding that Zeb1-driven EMT is necessary 
for metastasis also presented a potential lead to study drug resistance since several 
studies have suggested that EMT is a potential mechanism of radiation and 
chemotherapy resistance (38, 39). However, inhibition of Zeb1 or rescued expression 
of miR-200 is therapeutically infeasible due to the non-specific, pleiotropic nature of 
both genes as well as the challenges in delivering mature microRNAs clinically. 
Therefore we were interested in greater in-depth research into the precise mechanisms 
of Zeb1 and miR-200 to ultimately identify potential biomarkers and therapeutic target 
against lung cancer progression. 
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From our work that identified Zeb1/miR-200 as master regulators of EMT and 
metastasis in lung cancer (33), we made a significant observation that the invasiveness 
of metastatic lung cancer cells was dependent on their interaction with the surrounding 
extracellular matrix. When cultured in laminin-rich Matrigel, the mesenchymal cells 
displayed highly epithelial morphologies and phenotypes and only formed invasive 
structures upon stimulation with TGF-β. This suggested that the cell-intrinsic alterations 
of EMT is insufficient to drive an in vivo invasive and metastatic phenotype and that the 
reciprocal and dynamic interaction between lung cancer cells and the extracellular 
matrix is critical for the dissemination process. The use of TGF-β simulates an in vivo 
condition and is a known inducer of EMT and stimulates collagen deposition (67, 69, 
129), which we have demonstrated through in vitro 3D culture experiments to be 
necessary for the invasive phenotype (58). As there are numerous different types of 
collagen isoforms – each with variations in structural and biochemical properties that 
confer different biological consequences – the exact role of collagen on metastasis is 
not yet well-defined. Our bioinformatics analyses of the TCGA dataset, validated by 
qPCR, demonstrated that collagen type I and type III were upregulated in 
mesenchymal lung tumors and cancer cells. Collagen I and III are fibrillar collagens that 
are two of the most abundant collagen isoforms found in the body. Although our 
findings are consistent with breast cancer models that demonstrate that the presence 
of fibrillar collagen I is necessary for invasion and metastasis (62, 63), our findings 
here, in concordance with previous related work by our group (58), suggest that 
collagen-associated invasion/metastasis is due to ligand-based interaction with the 
Integrin β1/Fak/Src signaling pathway but not due to mechanical stiffening of the matrix 
(62, 65, 130-133). Although our data does show that the presence of crosslinked 
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collagen stiffens the tumor tissue, this is a consequence of increased collagen matrix 
content that can be mimicked by other matrices such as Matrigel or an ECM-deficient 
PEG hydrogel (134). In fact, when we cultured our invasive/metastatic 344SQ or 393P-
Zeb1 overexpressing cells in 3D in vitro PEG hydrogels of varying densities and 
stiffness, the cells always formed epithelial, spherical structures in high stiffness gels 
with no invasive protrusions even with the treatment of TGF-β (65), suggesting that 
collagen ligand is necessary for invasion and metastasis. Further emphasizing this 
point, when we cultured our mesenchymal cells in collagen mixed with ribose – a 
method of collagen stiffening by glycation (135) – we observed no difference, or a 
decrease, in the invasiveness of the lung cancer cells (Figure 129). 
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Figure 129 Figure 129. 344SQ cells cultured in 1.5 mg/mL collagen:Matrigel mix in the 
presence of PBS control, ribose, TGF-β, or TGF-β+ribose in combination. Bright 
field microscopy images at 4x magnification. 
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These conflicting reports demonstrate the complexities regarding the effects of collagen 
on cancer cell biology. In addition to individual collagen molecule ligand binding, the 
copious post-translational modifications of collagen also have a profound impact on 
how cells respond to the matrix protein. Moreover, manipulating collagen in an in vitro 
setting is also challenging due to collagen acquiring different properties depending on 
how the gel is prepared. For instance, we and others have demonstrated that collagen 
will spontaneously form covalent crosslinks during polymerization that is observable by 
SHG microscopy (56, 136). The longer the collagen remains as a liquid solution on ice, 
the more crosslinks will form. Furthermore, the compositional properties of the collagen 
gel also have an impact on the collagen crosslinks, resulting in different cancer cell 
response in 3D culture. For example, when we mixed a low concentration of collagen 
with Matrigel, we did not observe collagen crosslinks by SHG (Figure 9) compared to 
high concentrations of collagen. This increase in collagen crosslinks increases the 
invasiveness of the mesenchymal lung cancer cells which is consistent with previous 
reports (Figure 130) (136, 137). 
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Figure 130 
Figure 130. 393P-Zeb1 mesenchymal cells cultured in 1.5 mg/mL or 3 mg/mL final 
concentration of collagen mixed at a 1:1 ratio with Matrigel. Bright field microscopy 
images at 4x magnification. 
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 Although higher concentrations of collagen and crosslinks increase matrix 
stiffness, the mesenchymal lung cancer cells still formed invasive protrusions at low 
collagen concentrations despite the unobservable crosslinks by SHG microscopy. This 
denotes that the ligand property of collagen is important for invasion. However, as seen 
in Figure 8 and our previous studies, only mesenchymal lung cancer cells form the 
invasive structures when cultured at low collagen concentrations while epithelial cells 
do not. This supports the statement that there is a dynamic interplay between the 
mesenchymal lung cancer cells and their surrounding ECM. Previous studies have 
demonstrated that collagen interaction with lung cancer cells promotes EMT through 
TGF-β signaling (69). Interestingly, we previously demonstrated that only mesenchymal 
lung cancer cells lines are sensitive to TGF-β stimulation (33). Furthermore, our 
mesenchymal lung cancer cells not only basally express high levels of collagen, but 
when treated with TGF-β the collagen expression levels dramatically increase. This 
suggests that in an in vivo environment collagen deposition by lung cancer cells acts in 
a feed-forward loop that further promotes EMT. Additionally, we previously 
demonstrated that lung cancer cell interaction with collagen stimulates Integrin/Fak/Src 
signaling through an EMT-dependent manner. Taken together, our results present a 
novel mechanism by which EMT-induced collagen deposition activates invasive cell 
signaling pathways in an autocrine fashion to drive lung cancer metastasis. 
 Our clinical data demonstrate that increased collagen expression correlates with 
EMT and is associated with poorer overall survival in lung adenocarcinoma patients, 
validating collagen as a promising biomarker of metastasis and survival. However, it is 
not therapeutically or pharmacologically feasible to target collagen directly. Fortunately, 
our bioinformatics analyses as well as qPCR data revealed that LOX and LOXL2 were 
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concurrently upregulated with collagen expression patterns in mesenchymal cells. LOX 
and LOXL2 are promising therapeutic targets since they are extracellular enzymes with 
a conserved catalytic region with reported inhibitors. The LOX family of enzymes has 
been shown in several tumor types – most notably in breast cancer – to promote tumor 
progression through various intracellular and extracellular mechanisms, including 
collagen crosslinking (62, 77, 78, 80, 83, 99, 100, 138-143). Functional studies 
revealed that LOXL2 was the primary isoform responsible for collagen crosslinking, 
deposition, and metastasis while LOX only had an in vitro effect on cell 
migration/invasion. This finding contrasts that of other tumor types which predominantly 
identify LOX as the primary isoform driving metastasis and collagen crosslinking. 
However, our histological data, bolstered by biochemical analyses, confirms LOXL2 
crosslinking of collagen. Although LOXL2 has been implicated to be involved in 
collagen crosslinking due to its conserved catalytic region, our study is the first to 
directly validate this function. As mentioned throughout the dissertation, collagen 
processing and biology is very complicated. A common misconception amongst 
investigators that perform 3D culture experiments with collagen gels is that the collagen 
solutions, typically purchased from a vendor, are uncrosslinked. However, most 
processed and purchased collagen type I gels are derived from rat tail collagen and 
dissolved in an acid solution. The collagen from the rat tails are already fully mature, 
deaminated collagen fibers and will readily form the spontaneous covalent crosslinks 
resulting from LOX/LOXL2 deamination of the lysine residues. This is consistent with 
our in vitro data which demonstrate no changes in invasiveness when LOXL2 levels are 
manipulated without introduction of additional collagen. Overexpression of LOXL2 in 
epithelial lung cancer cells will have no effect on the invasiveness of the cells since the 
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collagen is already crosslinked and the cells have to co-express collagen, which is 
basally low in epithelial cells. Furthermore, epithelial cancer cells have low affinity for 
collagen binding which results in low activation of signaling pathways that lead to 
invasion and metastasis. LOXL2 is the necessary final step in collagen maturation in 
vivo and is necessary for deposition of insoluble collagen in the tissue architecture. If 
individual collagen fibers are not deaminated by LOXL2, there would be no 
intermolecular covalent bonds and collagen will remain as a soluble protein. In fact, if 
rat tail collagen type I gels are treated with sodium borohydride – which reverses the 
covalent bonds formed by the deaminated lysine residues – the gels liquefy and can be 
dissolved readily in solution. More importantly, the covalent crosslinks between 
collagen fibers must be formed with one deaminated lysine residue and one aminated 
lysine residue (ε-amine) that has not been processed by LOXL2. Hence, if LOXL2 is 
overexpressed at super-physiological levels, we would expect there to be no metastatic 
disease even in mesenchymal tumors since the overexpression of LOXL2 will go 
overboard with the deamination of lysine residues and no covalent bonds will form 
since there are no more ε-amine groups. Therefore, any studies on LOX or LOXL2 
crosslinking of collagen and its role in metastasis must be performed with in vivo 
systems and cannot be done using overexpression systems. As a matter of fact if there 
are any studies that overexpress LOX or LOXL2 in cancer cells and observe deficient 
collagen crosslinking or diminished collagen-associated metastases, then the 
mechanisms reported must be re-evaluated. The findings from our study confirm that 
LOXL2 stabilizes insoluble collagen deposition responsible for metastasis but does not 
have an effect on primary tumor growth. Taking all of our mechanistic, functional, and 
clinical data into consideration, inhibition of LOXL2 in a clinical context must be done in 
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combination with other therapies that directly target the primary tumor to prevent 
metastatic disease often associated with first-line therapies. This study delineates a 
novel mechanism of KRAS mutant lung cancer metastasis whereby EMT-induced 
LOXL2 crosslinking, linearization, and deposition of collagen results in the activation of 
the Fak/Src signaling pathway to promote invasion and metastasis. 
 
Project 2: Epithelial-to-Mesenchymal Transition promotes MEK inhibitor 
resistance in KRAS mutant lung cancers through suppression of IL17rd 
 
 It is imperative to understand drug resistance mechanisms because KRAS 
mutant lung cancer patients who receive MEK inhibitors respond very poorly to 
targeted therapies and even chemotherapies (25, 26). The in vivo FDAome shRNA 
dropout screen in conjunction with RPPA proteomic profiling identified differential 
reliance on MAPK molecules for tumor maintenance between epithelial and 
mesenchymal lung cancer cells and identified decreased MAPK signaling during EMT. 
Consistent with our prior work (40, 56, 58, 120), the RPPA dataset confirmed 
decreased signaling proteins involved in metastasis and certain types of drug 
resistance in epithelial lung cancer cells, while data from the shRNA library screen 
provided numerous additional drug targets for future investigations to optimize 
combination therapies. More importantly, though, a significant advantage in applying 
the shRNA screen to our immunocompetent syngeneic model is the ability to detect 
target genes that may synergize with immunotherapies. This study demonstrates the 
advantages of combining a functional hairpin screen with high-throughput proteomic 
profiles to characterize tumor progression and drug resistance. 
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Utilizing our syngeneic and genetically engineered mutant mouse models, we 
showed that the epithelial subpopulation of lung cancer cells within the heterogeneous 
tumor tissue was responsive to MEK inhibition while mesenchymal cells were resistant. 
These results provide an explanation to the development of therapy resistance due to 
co-mutations with mutant KRAS (27). Our in vitro cell line and in vivo tumor growth 
assays demonstrate that MEK inhibitor resistance is a result of both innate and 
acquired EMT. Translation of our histologic observations from murine tumor tissues to 
human specimens displayed an inverse correlation between MAPK signaling and Zeb1, 
presenting EMT-related molecules as prospective biomarkers to predict for MEK 
inhibitor response in patients. 
Thorough investigation into the mechanism of MAPK stimulation by miR-200 in 
epithelial cells identified IL17RD as the primary activating factor and revealed direct 
Zeb1 repression of the IL17RD promoter. Our results directly link EMT to MAPK 
signaling regulation and dependency. Since re-expression of IL17RD alone activated 
MEK/ERK signaling and was sufficient to induce response to MEK inhibitors in 
mesenchymal lung cancer cells, these results suggest that IL17RD is potentially 
altering cell signaling patterns in a broader intracellular scope besides MAPK 
activation/inhibition. Analyses of human patient datasets inversely correlated IL17RD 
with ZEB1 mRNA expression which potentially defines IL17RD as an additional 
biomarker to predict MEK inhibitor sensitivity. 
Since IL17RD inhibits FGFR1-associated MAPK signaling, we looked at FGFR1 
expression levels in our system and saw a positive correlation between EMT and 
FGFR1, which is consistent with previous work exploring the role of FGFR1 in MEK 
inhibitor resistance through feedback reactivation of MAPK signaling (24, 144). 
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Conversely, IL17RD levels were high in epithelial cells and inversely correlated with 
FGFR1 levels. Although the published reports demonstrate that a combination of MEK 
inhibitors with RTK or FGFR1-specific inhibitors is able to reduce primary lung tumor 
growth, the studies do not address potential metastatic events following treatment, 
which is a major cause of lung cancer patient deaths (5, 145). Here, we validate that 
the class I HDAC inhibitor mocetinostat – currently undergoing multiple clinical trials 
(https://clinicaltrials.gov/ct2/results?term=mocetinostat) – is able to induce miR-200, 
revert EMT, and dramatically increase Il17rd expression resulting in an upregulation of 
MAPK signaling. Using our syngeneic tumor model to study drug response is superior 
to human cell line xenografts because we are able to capture the metastatic events 
following treatments as well as address the heterogeneity observed clinically in 
isogenic tumors. The in vivo drug treatment assays of the syngeneic tumors 
demonstrate that the combination of selumetinib with mocetinostat not only decreases 
primary tumor growth, but significantly reduces metastatic disease as well, providing 
pre-clinical rationale for a promising combinatorial treatment strategy in patients. This 
study establishes the mechanism of MAPK signaling regulation by EMT, utilizes murine 
models and human lung cancer specimens to predict response to MEK inhibitors, and 
validates a novel treatment strategy for lung cancer. 
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CHAPTER 5: FUTURE DIRECTIONS 
 
Project 1: ZEB1 Induces LOXL2-Mediated Collagen Stabilization and Deposition 
in the Extracellular Matrix to Drive Lung Cancer Invasion and Metastasis 
 
 The importance of the extracellular function of LOXL2 in promoting metastasis 
makes the enzyme a promising therapeutic target against lung cancer metastasis. 
Although BAPN is a small molecule inhibitor of in vitro LOXL2 enzymatic activity, our 
data – consistent with numerous other studies and a failed clinical trial – shows that 
BAPN is a poor drug to use clinically and alternative inhibitors are necessary to target 
this enzyme. Currently, there exists a monoclonal antibody that neutralizes LOXL2 and 
is in phase II clinical trials. However, the design of the clinical trial aims to treat patients 
with advanced, metastatic solid tumors with the LOXL2 inhibiting antibody. Based on 
our data, this is the incorrect way to approach this study because the tumors are 
already in an advanced stage and are metastatic therefore it is no longer useful to 
target the collagen crosslinking enzyme. Furthermore, we also demonstrate that LOXL2 
inhibition does nothing to the primary tumor growth therefore only treating these 
patients with LOXL2 will have no effect on primary or metastatic tumor size. 
Furthermore, LOXL2 also has a reported intracellular function in metastasis (83) and an 
antibody therapy will not be able to target the intracellular isoform of the enzyme. 
Therefore future studies will aim to develop novel small molecule inhibitors of LOXL2 
enzymatic activity to prevent metastasis. Besides only targeting metastasis, we will aim 
at studying the effects of combinatorial treatments with LOXL2 inhibitors and first-line 
radiation or chemotherapies in pre-clinical models of lung cancer because targeting 
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LOXL2 alone has no effect on the growth of the primary tumor which is still important 
for patient survival. Our in vitro 3D culture data shows that mechanical stiffening of the 
surrounding matrix reduces invasiveness even in collagen. This suggests that the 
cancer cells themselves are reorganizing and remodeling mature, crosslinked collagen 
when they come in contact with the ECM to facilitate invasion and metastasis. Future 
studies will aim at understanding how the cancer cells are reshaping their milieu to 
drive the malignant phenotype. Lastly, since overexpression of LOX in epithelial cells 
did not have the opposing effect as LOX knockdown in mesenchymal cells, this means 
that there are other intracellular factors that operate in tandem with LOX to drive the in 
vitro migratory phenotype. Additional research to identify LOX co-factors of cell motility 
will be important to understand fundamental cellular functions. 
 
Project 2: Epithelial-to-Mesenchymal Transition promotes MEK inhibitor 
resistance in KRAS mutant lung cancers through suppression of IL17rd 
 
As miR-200 activation of MAPK signaling is independent of mutational status, 
this suggests that this process is necessary for development. Further research into the 
developmental role of miR-200 activation of MAPK signaling through IL17RD will help 
elucidate this complex biological process. Further studies with our newly generated 
conditional miR-141/200c and KM mutant mice will not only elucidate the role of miR-
200 on tumor progression, but also provide us the means to understand various 
biological and developmental processes. Because IL17RD is critical during 
development (115, 146) and is a negative regulator of EMT (147, 148), future 
investigations will aim to delineate the role of IL17RD on lung cancer progression, 
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identify changes in global cell signaling patterns that may confer sensitivity to targeted 
therapies after rescued expression in mesenchymal lung cancer cells, and establish the 
role of IL17RD on mammalian development. Additionally, we would like to optimize 
IL17RD antibodies for IHC staining in human patient tumor samples and be able to 
predict response to MEK inhibitors. Lastly, the ability to predict sensitivity to MEK 
inhibition based upon EMT status will allow for the establishment of other drug 
combinations that target the resistant mesenchymal subpopulation of cancer cells such 
as immune checkpoint blockade. With regards to immune therapies, using the in vivo 
shRNA screen to identify differential dependencies between epithelial and 
mesenchymal lung cancer cells in nude or immunocompetent mice will also identify 
targeted therapies that synergize with immune checkpoint blockade. 
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